

REPORT OF THE 390th CELL EXCHANGE FEBRUARY 3, 2016

B-cell Lines	521-522
Cells	1557-1560
Serum	1185-1192

B-cell Line Exchange #261

The results for B-cell Line Exchange #261 are summarized in Tables 1 - 2 and individual laboratory results reported for each sample are listed in Tables

3 - 8. The haplotype frequencies used in this report are from the NMDP Bioinformatics website, <http://bioinformatics.nmdp.org/>.

Ter-521. The consensus type for this sample from a Filipino donor is DRB1*15:01-DRB1*15:02-DRB5*01:01-DQA1*01:02-DQB1*05:02-DPA1*01:03-DPA1*02:02-DPB1*01:01-DPB1*03:01-A*11:01-A*34:01-B*07-B*15:21-C*04:03-C*07:02. One likely class II association in this is DRB1*15:01-DRB5*01:01-DQA1*01:02-DQB1*05:02, observed in exchange cells Ter 482 (same as Ter 393) and Ter 243 (same as IHW9262). The other likely association in this cell is then DRB1*15:02-DRB5*01:01-DQA1*01:02-DQB1*05:02, observed in Ter 433 (same as Ter 269) from an Asian donor.

This cell was previously typed for class II as Ter 276 (2001), as correctly identified by Tiercy. In this present retyping, DRB1*15:01 and DRB1*15:02 were each assigned by 97% of labs reporting at high resolution. DRB1*15:01:01 was reported by 5 labs, and DRB1*15:02:01 was reported by 6 labs. This sample was homozygous for DRB5*01:01 (100%), DQA1*01:02 (100%), and DQB1*05:02 (97%).

This sample was also previously typed for class I as extracts 279 (2004) and 112 (1999). In this present study, A*11:01 and A*34:01 were each assigned by 95% of labs reporting at high resolution. A*11:01:01 and A*34:01:01 were each assigned by 4 labs. C*04:03 (95%) and C*07:02 (100%) were the C-locus types. For the B-locus, B*15:21 was well assigned by 96%. However, as in the 2004 typing, the assignment of the second B-locus allele remained unresolved, as 10 labs assigned B*07:06, 5 labs assigned B*07:05:01G, 3 labs assigned B*07:05, and 1 lab assigned B*07:05P. B*07:06 was found to differ from B*07:05 in exon 5 by a single nucleotide substitution at codon 282 (ATC → GTC) in which isoleucine is replaced by valine in B*07:06 (1).

Ter-522. The consensus type for this sample from a Chinese donor is DRB1*04:05-DRB1*08:14-DRB4*01:03-DQA1*01:03-DQA1*03-DQB1*04:01-DQB1*06:01-DPA1*02:02-DPB1*02:02-DPB1*05:01-A*02:03-A*11:01-B*15:02-B*38:02-C*07:02-C*08. One likely association in this cell may be DRB1*04:05-DRB4*01:03-DQA1*03-DQB1*04:01. DRB1*04:05-DQB1*04:01 is commonly observed in Asians, with HF=04545. The other likely association is then, DRB1*08:14-DQA1*01:03-DQB1*06:01.

This cell is KE, the reference cell for DRB1*08:14, as astutely noted by Tiercy. It is also known as FH44 and was studied in the workshops as cell IHW9432 and in the exchange as Ter 467 (2012), Ter 384 (2007), and Ter 334 (2004). In this present retyping, DRB1*08:14 was assigned by 94%, compared to 76% of labs assigning DRB1*08:14 in 2012. DRB1*04:05 was reported as the second DRB1 type by 97%. DQA1*01:03 (100%) was assigned in complete consensus. The assignment of the second DQA1 type, however, remained unresolved, as DQA1*03:03 was reported by 12 labs, DQA1*03:01:01G by 4 labs, and DQA1*03:01 by 3 labs.

A*02:03, A*11:01, B*15:02, and B*38:02 were all assigned by 95% of labs reporting at high resolutions. A*02:03:01, A*11:01:01, B*15:02:01, and B*38:02:01 were each reported by 4 labs. The presence of a possible new C-locus allele was noted by Arnold, Hartzman and Hurley, Renac, and Reed. The new allele is observed to differ from C*08:01 by 2 nucleotides changes in exon 4. One is at position 766, codon 232 (GAG → AAG), which results in an amino acid change from glutamic acid to lysine. The other is a silent mutation at position 855, codon 261 (GTG → GTA).

References:

1. Sanz L, Vilches R, de Pablo R, et al. Haplotypic association of two new HLA class I alleles: Cw*15052 and B*0706: evolutionary relationships of HLA -Cw*15 alleles. Tissue Antigens 1996; 47:329-332.

Table 2: Summary of the 261st B-cell Line Exchange

Ter-522

DNA Typing - class II

<u>34 labs High; 34 labs low-DRB1</u>		%(n)
DRB1*04:05:01		18(6)
DRB1*04:05		79(27)
<i>DRB1*15:01</i>		3 (1)
DRB1*04		100(34)
<u>36 labs High; 30 labs low-DRB1</u>		%(n)
DRB1*08:14		94(34)
<i>DRB1*15:02</i>		3 (1)
<i>DRB1*04:05</i>		3 (1)
DRB1*08		83(25)
DRB1*04		17(5)

<u>20 labs High; 25 labs Low-DRB4</u>		%(n)
DRB4*01:03		90(18)
<i>DRB4*01:01</i>		5 (1)
DRB4*01:01+		5 (1)
DRB4*01		76(19)
DRB4*PRESENT		14(6)

<u>20 labs High; 23 labs Low-DQA1</u>		%(n)
DQA1*01:03		100(20)
DQA1*01		100(23)
<u>19 labs High; 23 labs Low-DQA1</u>		%(n)
DQA1*03:01:01G		21(4)
DQA1*03:03		63(12)
DQA1*03:01		16(3)
DQA1*03		100(23)

<u>30 High Labs; 33 labs Low-DQB1</u>		%(n)
DQB1*04:01:01		17(5)
DQB1*04:01		80(24)
<i>DQB1*05:02</i>		3 (1)
DQB1*04		100(33)
<u>30 High Labs; 36 labs Low-DQB1</u>		%(n)
DQB1*06:01:01		13(4)
DQB1*06:01		83(25)
<i>DQB1*05:02</i>		3 (1)
DQB1*06		100(33)

<u>12 High Labs; 15 labs Low-DPA1</u>		%(n)
DPA1*02:02:02		8 (1)
DPA1*02:02		92(11)
DPA1*02		100(15)
<u>29 High Labs; 15 labs Low-DPB1</u>		%(n)
DPB1*02:02		97(28)
<i>DPB1*148:01</i>		3 (1)
DPB1*02		100(15)
<u>29 High Labs; 15 labs Low-DPB1</u>		%(n)
DPB1*05:01:01		10(3)
DPB1*05:01:01G		17(5)
DPB1*05:01P		7 (2)
DPB1*05:01		66(19)
DPB1*05		100(15)

Serology - class II

<u>3 LABS- DR</u>		%(n)
DR4		100(3)

<u>3 LABS - DRX</u>		%(n)
DR53		100(3)

<u>3 LABS - DQ</u>		%(n)
DQ1		100(3)
DQ4		100(2)

DNA Typing - class I

<u>22 labs High; 24 labs low- A</u>		%(n)
A*02:03:01		18(4)
A*02:03		77(17)
<i>A*34:01</i>		5 (1)
A*02		96(23)
A*02(A203)		4 (1)
<u>20 labs High; 24 labs low- A</u>		%(n)
A*11:01:01		20(4)
A*11:01		75(15)
<i>A*11:54</i>		5 (1)
A*11		100(24)

<u>22 labs High; 24 labs low- B</u>		%(n)
B*15:02:01		18(4)
B*15:02		77(17)
<i>B*15:21</i>		5 (1)
B*15		91(22)
B*15(B75)		9 (2)
<u>21 labs High; 24 labs low- B</u>		%(n)
B*38:02:01		19(4)
B*38:02		76(16)
<i>B*07:06</i>		5 (1)
B*38		100(24)

<u>19 labs High; 25 labs low- C</u>		%(n)
C*07:02:01:01		5 (1)
C*07:02:01G		11(2)
C*07:02P		5 (1)
C*07:02		63(12)
<i>C*07:90</i>		5 (1)
<i>C*07:260</i>		5 (1)
C*NEW		5 (1)
C*07		100(25)
<u>19 labs High; 25 labs low- C</u>		%(n)
C*08:01:01G		11(2)
C*08:01:01		5 (1)
C*08:01P		5 (1)
C*08:01		58(11)
<i>C*08:72</i>		5 (1)
<i>C*04:03</i>		5 (1)
C*NEW		11 (2)
C*08		100(25)

Table 3a: Individual laboratory results for B-cell #521-Class II

Center	Investigator	Low resolution												METHOD	Other Alleles
		DRB1	DRB5	DQA1	DQB1	DPA1	DPB1								
5488	Adams , Sharon		5*01											SSP SSO SBT	
4691	Al Ajlan , Abdulaziz						*05	*05							
5133	Askar , Medhat	*15	*15	5*01		*01		*05		*01	*02			SSO SBT	
774	Cecka , J. Michael	*15		5*01		*01		*05		*01	*02	*01	*03		
3632	Colombe , Beth W.	*15	*15	5*01		*01		*05		*01	*02	*01	*03	SSP SSO	
5130	Costeas , Paul A.	*15	*15					*05	*05					SSP SSO	
779	Daniel , Claude	*15	*15	5*01	5*01	*01		*05		*01	*02	*01	*03	SSP SSO	
5219	Daniel , Dolly	*15	*15					*05	*05						
1108	DeConinck , Martha	*15		5*01		*01		*05		*01	*02	*01	*03	SSO	
3766	Dunckley , Heather	*15	*15	5*01		*01		*05		*01	*02	*01	*03	SSP SSO RT-PCR	
5214	Eckels/CPMC ,	*15	*15	5*01		*01		*05	*05					SSO	
792	Gandhi , Manish	*15	*15	5*01		*01		*05		*01	*02	*01	*03	SSP SSO SBT	
910	Hahn , Amy B.	*15	*15	5*PRESENT	5*PRESENT			*05	*05					SSP	
1694	Hesse , Nicole	*15		5*PRESENT				*05						SSP	
8043	Hod , Reut	*15	*15			*01		*05						SSP SSO	
771	Israel , Shoshana	*15						*05						SSP SSO	
794	Jaatinen , Taina	*15		5*01		*01		*05		*01	*02	*01	*03	SSP SSO SBT RT-PCR	
2847	Kihara , Masaaki	*15	*15											SSO	
87	Land , Geoffrey A.	*15	*15	5*01	5*01	*01	*01	*05	*05	*01	*02	*01	*03	SSP	
725	Lardy , N.M.	*15		5*PRESENT		*01		*05						SSP SSO	
278	Lee , Jar-How	*15	*15	5*01	5*01	*01	*01	*05	*05	*01	*02	*01	*03		
6649	Lim , Young Ae	*15		5*PRESENT										SSP	
759	Lopez-Cepero , May	*15		5*01		*01		*05		*01	*02	*01	*03	SSP SSO	DPB1*78
206	McAlack-Hanau ,	*15	*15	5*01		*01		*05	*05	*01	*02	*01	*03		
8042	Muncher , Liora	*15	*15	5*01	5*01	NT	NT	*05	*05	NT	NT	NT	NT	SSP SSO	
54	Pancoska , Carol	*15		5*01		*01		*05		*01	*02	*01	*03	SSO	
3966	Permpikul , Vejbaes	NT													
2400	Phelan , Donna L.	*15	*15	5*01	NP	*01		*05				*01	*03		
8001	Rao , Prakash					*01									
3519	Renac , Virginie	*15						*05				*01	*03	SSP SBT	
1160	Rosen-Bronson , Sa	*15		5*01		*01		*05		*01	*02			SSO SBT	
793	Rubocki , Ronald	*15		5*PRESENT		*01		*05				*01	*03	SSP	
4251	Schiller , Jennifer	*15	*15	5*01	5*01	*01	*01	*05	*05	*01	*02	*01	*03	SSO SBT	
8068	Shanmugam , Hem	*15	*15			*01	*01	*05	*05					SSO	
8029	Tarigopula , Anil	*15	*15					*05	*05					SSO	
747	Tiercy , Jean-Marie	*15	*15			*01		*05						SSP SSO SBT	
5451	Tilanus , Marcel G.J.	*15	*15	5*PRESENT				*05						SSP SBT	
5642	Varnavidou-Nicolaic	*15		5*PRESENT				*05						SSP	
8052	Yanina Marcos , Cir	*15	*15			*01	*01	*05	*05					SSO	

Table 3b: Individual laboratory results for B-cell #521-Class II									
Serology									
CTR	DIRNAME	DR15		DR51		DQ1		OTH1	OTH2
4492	Charron,D.	+		+		+		DR13	
910	Hahn,Amy B.	+		+		+			
4908	Kvam,Vonnett	+		+		+			

Table 4: Individual laboratory results for B-cell #521-Class II

Center	Investigator	High resolution										METHOD	Other Alleles	
		DRB1	DRB5	DQA1		DQB1		DPA1		DPB1				
5488	Adams , Sharon	*15:01:01	*15:02:01		*01:02		*05:02:01				*01:01:01	*03:01:01	SSP SSO SBT	DQA1*01:11
4691	Al Ajlan , Abdulaziz	*15:01	*15:02											
5462	Arnold , Paula	*15:01	*15:02	5*01:01	NT	NT	*05:02		NT	NT	*01:01	*03:01	SSP SSO SBT	DRB5*01:15
5133	Askar , Medhat	*15:01	*15:02	5*01:01					*01:03	*02:02	*01:01:01G	*03:01	SSO SBT	DRB1*15:74/15:85/15:86/15:106/15:107/15:108/15:110/15:111/15:112, DPB1*222:01/270:01/293:01/326:01/327:01/329:01/346:01, DRB5*01:15,
774	Cecka , J. Michael	*15:01	*15:02	5*01:01	*01:02		*05:02	*05:05	*01:03	*02:02	*01:01	*03:01	SBT	DRB1*15:85/15:86/15:106/15:107/15:108/15:111/15:112/15:113N, DRB5*01:15, DQB1*05:14/05:17/05:19/05:26/05:33/05:34/05:36/05:37/05:46/05:47/05:57/05:58 /05:87Q
8070	Chang , Uckjin	*15:01	*15:02										SSP SBT	
9916	Charlton , Ronald K	*15:01:01	*15:02:01	5*01:01			*05:02:01				*01:01:01	*03:01:01	SSP SBT	
4492	Charron , Dominiqu	*15:01	*15:02	5*01:01	*01:02		*05:02		*01:03	*02:02	*01:01	*03:01	SSP SSO	DRB1*15:74/15:85/15:86/15:106/15:107, DRB1*05:14/05:17/05:19/05:26/05:33/05:34, DQA1*01:08/01:09/01:11, DPB1*104:01
8021	Clark , Brendan	*15:01	*15:02	5*01:01	*01:02		*05:02				*01:01	*03:01	SSP SSO	
3632	Colombe , Beth W.	*15:01	*15:02	5*01:01	*01:02		*05:02		*01:03	*02:02	*01:01	*03:01	SSP SSO	
5130	Costeas , Paul A.	*15:01	*15:02	5*01:01	*01:02	*01:02	*05:02	*05:02					SSP SSO	
779	Daniel , Claude				*01:02				*01:03	*02:02	*01:01	*03:01	SSP SSO	
3766	Dunckley , Heather										*01:01	*03:01	SSP SSO RT-PCR	
5214	Eckels/CPMC ,								*01:03	*02:02	*01:01:01G	*03:01:01G	SSO	
3135	Enczmann , J	*15:01	*15:02	5*01:01			*05:02	*05:02			*01:01	*03:01	SSP SSO SBT	
762	Fischer , Gottfried	*15:01	*15:02	5*01:01	*01:02		*05:02				*01:01	*03:01	SSP SSO SBT	DQB1*05:47
4079	Fort , Marylise	*15:01	*15:02				*05:02				*01:01	*03:01	SSP SSO	DPB1*104:01, DRB1*15:113N/15:116, DQB1*05:87Q
792	Gandhi , Manish	*15:01	*15:02	5*01:01	*01:02		*05:02				*01:01	*03:01	SSP SSO SBT	
810	Hamdi , Nuha	*15:01	*15:02	5*01:01	*01:02	*01:02	*05:02	*05:02					SSO	
8043	Hod , Reut	*15:01	*15:02		*01:02		*05:02						SSP SSO	

Table 4: Individual laboratory results for B-cell #521-Class II

Center	Investigator	High resolution											METHOD	Other Alleles
		DRB1		DRB5	DQA1		DQB1		DPA1		DPB1			
2344 771	Hurley , Hartzman & Israel , Shoshana	*15:01:01:01 *15:01	*15:02:01 *15:02		*01:02:01:01	*01:02:02	*05:02:01 *05:02	*05:02:01	*01:03:01:03	*02:02:02	*01:01:01	*03:01:01	OTHER SSP SSO	DQA1*01:02:01:03, DPB1*104:01, DRB1*15:01:01:02/15: 01:01:03/15:01:01:04
794	Jaatinen , Taina	*15:01	*15:02	5*01:01	*01:02		*05:02		*01:03	*02:02	*01:01	*03:01	SSP SSO SBT RT-PCR	DRB1*15:86, DQA1*01:08/01:09/01: 11
8086	Jie , Pan	*04:05	*08:14				*06:01	*04:01					SSP SSO SBT	
4337	Kim , Tai-Gyu	*15:01	*15:02				*05:02	*05:02			*01:01	*03:01	SBT	
278	Lee , Jar-How	*15:01	*15:02	5*01:01	*01:02	*01:02	*05:02	*05:02	*01:03	*02:02	*01:01	*03:01		
759	Lopez-Cepero , May										*01:01P	*03:01P	SSP SSO	
731	Loewenthal , Ron	*15:01:01	*15:02:01				*05:02:01						SSO SBT	DRB1*15:01:17
8042	Muncher , Liora	*15:01	*15:02	5*01:01	NT	NT	*05:02	*05:02	NT	NT	NT	NT	SSP SSO	
54	Pancoska , Carol								*01:03	*02:02			SSO	
3966	Permpikul , Vejbaes	NT												
2400	Phelan , Donna L.	*15:01	*15:02		*01:02		*05:02				*01:01:01G	*03:01:01G		
8001	Rao , Prakash	*15:01	*15:02	5*01:01				*05:02			*01:01	*03:01		DPB1*104:01
3753	Reed , Elaine F.	*15:01	*15:02	5*01:01	*01:02:01G	*01:02:01G	*05:02	*05:02	*01:03	*02:02	*01:01	*03:01	SSO SBT OTHER	DRB5*01:15, DPB1*326:01/327:01/3 46:01, DPB1*104:01/221:01/2 22:01/270:01/293:01/3 29:01
3519	Renac , Virginie	*15:01	*15:02	5*01:01	*01:02		*05:02				*01:01	*03:01	SSP SBT	
1160	Rosen-Bronson , Sa	*15:01	*15:02	5*01:01			*05:02		*01:03	*02:02	*01:01	*03:01	SSO SBT	
793	Rubocki , Ronald										*01:01	*03:01	SSP	
4251	Schiller , Jennifer	*15:01	*15:02				*05:02	*05:02			*01:01:01G	*03:01:01G	SSO SBT	
747	Tiercy , Jean-Marie	*15:01	*15:02:01	5*01:01	*01:02		*05:02:01				*01:01	*03:01	SSP SSO SBT	DQA1*01:08/01:09/01: 11
5451	Tilanus , Marcel G.	*15:01:01	*15:02:01										SSP SBT	
5642	Varnavidou-Nicolaic	*15:01	*15:02				*05:02	*05:02					SSP	DRB1*15:33/15:39, DQB1*05:01
3511	Zeevi , Adriana	*15:01	*15:02	5*01:01	*01:02		*05:02				*01:01	*03:01	SSP SSO	

Table 5: Individual laboratory results for B-cell #521-Class I

Center	Investigator	Low Resolution						Intermediate/High resolution						METHOD	Other Alleles
		HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C			
5488	Adams , Sharon							*11:01:01	*34:01:01	*07:05:01/06	*15:21	*04:03:01	*07:02:01	SSP SSO SBT	C*07:50/07:349
4691	Al Ajlan , Abdulaziz	*11	*34	*07	*15	*04	*07								
5462	Arnold , Paula							*11:01	*34:01	*07:05P	*15:21	*04:03	*07:02	SSP SSO SBT	
5133	Askar , Medhat	*11	*34	*07	*15	*04	*07	*11:01:01	*34:01:01	*07:06	*15:21	*04:03:01	*07:02:01	SSO SBT	C*07:349
774	Cecka , J. Michael	*11	*34	*07	*15	*04	*07				*15:21	*04:03			C*04:160/04:171
9916	Charlton , Ronald K							*11:01:01	*34:01:01	*07:06	*15:21	*04:03:01	*07:02:01	SSP SBT	
4492	Charron , Dominiqu							*11:01	*34:01	*07:06	*15:21	*04:03	*07:02	SSP SSO	A*11:20/11:100/11:154/11:163/11:173/11:174/11:179+, B*07:159/07:195/07:213/07:245/07:306/07:319/07:320
8021	Clark , Brendan							*11:01	*34:01	*07:06	*15:21	*04:03	*07:02	SSP SSO	
5130	Costeas , Paul A.	*11	*34	*07	*15	*04	*07	*11:01	*34:01	*07:06	*15:21	*04:03	*07:02	SSP SSO	A*11:10
779	Daniel , Claude	*11	*34	*07	*15	*04	*07				*15:21			SSP SSO	
5219	Daniel , Dolly	*11	*34	*07	*15	*04	*07								
1108	DeConinck , Martha	*11	*34	*07	*15	*04	*07							SSO	
3766	Dunckley , Heather	*11	*34	*07	*15	*04	*07							SSP SSO RT-PCR	
5214	Eckels/CPMC ,	*11	*34	*07		*04	*07				*15:21			SSO	
3135	Enczmann , J							*11:01	*34:01	*07:05	*15:21	*04:03	*07:02	SSP SSO SBT	
792	Gandhi , Manish	*11	*34	*07	*15	*04	*07	*11:01	*34:01	*07:06	*15:21	*04:03	*07:02	SSP SSO SBT	
810	Hamdi , Nuha							*11:54	*34:01	*07:05	*15:21			SSO	
1694	Hesse , Nicole	*11	*34	*07	*15	*04	*07							SSP	
2344	Hurley , Hartzman&							*11:01:01	*34:01:01	*07:06	*15:21	*04:03:01	*07:02:01:01	OTHER	
794	Jaatinen , Taina	*11	*34	*07	*15	*04	*07	*11:01	*34:01	*07:05/06	*15:21	*04:03	*07:02	SSP SSO SBT RT-PCR	C*07:50
8086	Jie , Pan							*11:01	*02:03	*38:02	*15:02	*08:01:06	*07:02:35	SSP SSO SBT	C*07:13/07:161/07:260, C*08:16:01/08:72:01, C*08:59
2847	Kihara , Masaaki	*11	*34	*07	*15	*04	*07							SSO	
87	Land , Geoffrey A.	*11	*34	*07	*15(B75)	*04	*07							SSP	
4337	Kim , Tai-Gyu							*11:01	*34:01	*07:05	*15:21	*04:03	*07:02	SBT	
278	Lee , Jar-How	*11	*34	*07	*15	*04	*07	*11:01	*34:01	*07:06	*15:21	*04:03	*07:02		
206	McAlack-Hanau ,	*11	*34	*07	*15	*04	*07								
8042	Muncher , Liora	*11	*34	*07	*15	*04	*07	*11:01	*34:01	*07:06	*15:21	*04:03	*07:02	SSP SSO	
54	Pancoska , Carol	*11	*34	*07	*15	*04	*07				*15:21			SSO	
2400	Phelan , Donna L.	*11	*34	*07	*15	*04	*07	*11:01	*34:01	*07:05:01G	*15:21	*04:03	*07:02:01G		
3519	Renac , Virginie	*11	*34	*07	*15	*04	*07							SSP SBT	
3753	Reed , Elaine F.							*11:01	*34:01	*07:05:01G	*15:21	*04:03	*07:02	SSO SBT OTHER	C*04:06, C*07:37/07:50/07:349
3519	Renac , Virginie							*11:01	*34:01	*07:06	*15:21	*04:03	*07:02	SSP SBT	
4251	Schiller , Jennifer	*11	*34	*07	*15	*04	*07	*11:01	*34:01	*07:05:01G	*15:21	*04:03	*07:02	SSO SBT	
8068	Shanmugam , Hem	*11	*34	*07	*15	*04	*07							SSO	
8029	Tarigopula , Anil	*11	*34	*07	*15	*04	*07							SSO	
8052	Yanina Marcos , Cil	*11	*34	*07	*15	*04	*07				*15:21			SSO	

Table 6a: Individual laboratory results for B-cell #522-Class II

		Low resolution													
Center	Investigator	DRB1		DRB5		DQA*01		DQB1		DPA1		DPB1		METHOD	Other Alleles
5488	Adams , Sharon			4*01										SSP SSO SBT	
4691	Al Ajlan , Abdulaziz							*04	*06						
5133	Askar , Medhat	*04	*08	4*01		*01	*03	*04	*06	*02				SSO SBT	
774	Cecka , J. Michael	*04	*08	4*01		*01	*03	*04	*06	*02		*02	*05		
3632	Colombe , Beth W.	*04	*08	4*01		*01	*03	*04	*06	*02		*02	*05	SSP SSO	
5130	Costeas , Paul A.	*04	*08					*04	*06					SSP SSO	
779	Daniel , Claude	*04	*08	4*01	4*01	*01	*03	*04	*06	*02		*02	*05	SSP SSO	
5219	Daniel , Dolly	*04	*04					*04	*06						
1108	DeConinck , Martha	*04		4*01		*01	*03	*04	*06	*02		*02	*05	SSO	
3766	Dunckley , Heather	*04	*08	4*01		*01	*03	*04	*06	*02		*02	*05	SSP SSO RT-PCR	
5214	Eckels/CPMC ,	*04		4*01		*01	*03	*04	*06					SSO	
792	Gandhi , Manish	*04	*08	4*01		*01	*03	*04	*06	*02		*02	*05	SSP SSO SBT	
910	Hahn , Amy B.	*04	*04	4*PRESENT	4*PRESENT			*04	*06					SSP	
1694	Hesse , Nicole	*04		4*PRESENT				*04	*06					SSP	
8043	Hod , Reut	NT												SSP SSO	
771	Israel , Shoshana	*04						*04	*06					SSP SSO	
794	Jaatinen , Taina	*04	*08	4*01		*01	*03	*04	*06	*02		*02	*05	SSP SSO SBT RT-PCR	
2847	Kihara , Masaaki	*04	*08											SSO	
87	Land , Geoffrey A.	*04	*04	4*01	4*01	*01	*03	*04	*06	*02	*02	*02	*05	SSP	
725	Lardy , N.M.	*04	*08	4*PRESENT		*01	*03	*04	*06					SSP SSO	
278	Lee , Jar-How	*04	*08	4*01	NT	*01	*03	*04	*06	*02	*02	*02	*05		
6649	Lim , Young Ae	*04	*08		4*PRESENT									SSP	
759	Lopez-Cepero , Ma	*04	*08	4*01		*01	*03	*04	*06	*02		*02	*05	SSP SSO	DPB1*38
206	McAlack-Hanau ,	*04	*08	4*01		*01	*03	*04	*06	*02		*02	*05		
8042	Muncher , Liora	*04	*08	4*01	NP	NT	NT	*04	*06	NT	NT	NT	NT	SSP SSO	
54	Pancoska , Carol	*04	*08	4*01		*01	*03	*04	*06	*02			*05	SSO	
3966	Permpikul , Vejbaes	NT													
2400	Phelan , Donna L.	*04	*08	4*01	NP	*01	*03	*04	*06			*02	*05		
8001	Rao , Prakash					*01	*03								
3519	Renac , Virginia	*04	*08					*04	*06			*02	*05	SSP SBT	
1160	Rosen-Bronson , S	*04	*08	4*01		*01	*03	*04	*06	*02				SSO SBT	
793	Rubocki , Ronald	*04	*08	4*PRESENT		*01	*03	*04	*06			*02		SSP	
4251	Schiller , Jennifer	*04	*08	4*01		*01	*03	*04	*06	*02	*02	*02	*05	SSO SBT	
8068	Shanmugam , Hem	*04	*04			*01	*03	*04	*06					SSO	
8029	Tarigopula , Anil	*04	*04					*04	*06					SSO	
747	Tiercy , Jean-Marie	*04	*08			*01	*03	*04	*06					SSP SSO SBT	
5451	Tilanus , Marcel G.	*04	*08	4*PRESENT				*04	*06					SSP SBT	
5642	Varnavidou-Nicola	*04	*08	4*PRESENT				*04	*06					SSP	
8052	Yanina Marcos , C	*04	*08			*01	*03	*04	*06					SSO	

Table 6b: Individual laboratory results for B-cell #522-Class II								
Serology								
CTR	DIRNAME	DR4		DR53	DQ1	DQ4	OTH1	OTH2
4492	Charron,D.	+		+	+	+	DR1,DR8	DR14
910	Hahn,Amy B.	+		+	+	+	DR1	
4908	Kvam,Vonnett	+		+	+		DR8,DQ8	

Table 7: Individual laboratory results for B-cell #522-Class II

Intermediate/High resolution														
Center	Investigator	DRB1		DRB4	DQA1		DQB1		DPA1		DPB1		METHOD	Other Alleles
5488	Adams , Sharon	*04:05:01	*08:14		*01:03	*03:03	*04:01:01	*06:01:01			*02:02	*05:01:01	SSP SSO SBT	DQA1*01:10
4691	Al Ajan , Abdulaziz	*04:05	*08:14											
5462	Arnold , Paula	*04:05	*08:14	4*01:03	NT	NT	*04:01	*06:01	NT	NT	*02:02	*05:01	SSP SSO SBT	
5133	Askar , Medhat	*04:05	*08:14		*01:03						*02:02	*05:01:01G	SSO SBT	DRB1*04:178N, DQA1*01:10
774	Cecka , J. Michael	*04:05	*08:14	4*01:03	*01:03	*03:03	*04:01	*06:01	*02:02		*02:02	*05:01		DRB1*04:78N, DRB4*01:09, DQB1*04:07/04:14/04:15/04:16/04:17, DQB1*06:99/06:105
8070	Chang , Uckjin	*04:05											SBT	
9916	Charlton , Ronald K	*04:05:01	*08:14	4*01:03			*04:01:01	*06:01			*02:02	*05:01:01	SSP SBT	DRB4*01:09
4492	Charron , Dominique	*04:05	*08:14	4*01:03	*01:03	*03:01/02/03	*04:01	*06:01	*02:02		*02:02	*05:01	SSP SSO	DRB1*04:178N, DQA1*01:10, DQB1*04:07/04:14/04:15/04:16/04:17, DQB1*06:43/06:99/06:100/06:101/06:102N , DPB1*135:01
8021	Clark , Brendan	*04:05	*08:14	4*01:03	*01:03	*03:01	*04:01	*06:01			*02:02	*05:01	SSP SSO	
3632	Colombe , Beth W.	*04:05	*08:14	4*01:03	*01:03	*03:03	*04:01	*06:01	*02:02		*02:02	*05:01	SSP SSO	
5130	Costeas , Paul A.	*04:05	*08:14	4*01:03	*01:03	*03:03	*04:01	*06:01					SSP SSO	
779	Daniel , Claude		*08:14		*01:03	*03:03					*02:02	*05:01	SSP SSO	
3766	Dunckley , Heather		*08:14								*02:02	*05:01	SSP SSO RT-PCR	
5214	Eckels/CPMC ,		*08:14						*02:02		*148:01	*05:01:01G	SSO	
3135	Enczmann , J	*04:05	*08:14	4*01:03			*04:01	*06:01			*02:02	*05:01	SSP SSO SBT	
762	Fischer , Gottfried	*04:05	*08:14	4*01:03	*01:03	*03:03	*04:01	*06:01			*02:02	*05:01	SSP SSO SBT	DQB1*06:105
4079	Fort , Marylise	*04:05	*08:14				*04:01	*06:01			*02:02	*05:01	SSP SSO	DPB1*135:01
792	Gandhi , Manish	*04:05	*08:14	4*01:03	*01:03	*03:03	*04:01	*06:01			*02:02	*05:01	SSP SSO SBT	
810	Hamdi , Nuha	*04:05	*08:14	4*01:01	*01:03	*03:01	*04:01	*06:01					SSO	
8043	Hod , Reut	NT											SSP SSO	
2344	Hurley , Hartzman&	*04:05:01	*08:14		*01:03	*03:02/03:03:01	*04:01:01	*06:01:01	*02:02:02	*02:02:02	*02:02	*05:01:01	OTHER	DQA1*01:03:01:02, DPB1*135:01
771	Israel , Shoshana	*04:05					*04:01	*06:01					SSP SSO	
794	Jaatinen , Taina	*04:05	*08:14	4*01:03	*01:03	*03:01/02/03	*04:01	*06:01	*02:02		*02:02	*05:01	SSP SSO SBT RT-PCR	DPB1*135:01, DQA1*01:10
8086	Jie , Pan	*15:01	*15:02				*05:02	*05:02					SSP SSO SBT	
4337	Kim , Tai-Gyu	*04:05	*04:05				*04:01	*06:01			*02:02	*05:01	SBT	
278	Lee , Jar-How	*04:05	*08:14	4*01:03	*01:03	*03:03	*04:01	*06:01	*02:02	02:02	*02:02	*05:01		
759	Lopez-Cepero , Ma										*02:02	*05:01P	SSP SSO	
731	Loewenthal , Ron	*04:05:01					*04:01:01	*06:01:01					SSO SBT	DQB1*04:08, DQB1*06:45
8042	Muncher , Liora	*04:05	*08:14	4*01:03	NT	NT	*04:01	*06:01	NT	NT	NT	NT	SSP SSO	
54	Pancoska , Carol		*08:14						*02:02				SSO	

Table 7: Individual laboratory results for B-cell #522-Class II

Intermediate/High resolution														
Center	Investigator	DRB1	DRB4	DQA1	DQB1	DPA1	DPB1	METHOD	Other Alleles					
3966	Permpikul , Vejbaes	NT												
2400	Phelan , Donna L.	*04:05	*08:14		*01:03	*03:03	*04:01	*06:01			*02:02	*05:01P		
8001	Rao , Prakash	*04:05	*08:14	4*01:03			*04:01	*06:01			*02:02	*05:01		
3753	Reed , Elaine F.	*04:05	*08:14	4*01:01/0 3/06/08	*01:03	*03:01:01G	*04:01	*06:01	*02:02	*02:02	*02:02	*05:01:01G	SSO SBT OTHER	DQA1*01:10
3519	Renac , Virginie	*04:05	*08:14	4*01:03	*01:03	*03:03	*04:01	*06:01			*02:02	*05:01	SSP SBT	
1160	Rosen-Bronson , S	*04:05	*08:14	4*01:03	*01:03	*03:03	*04:01	*06:01	*02:02		*02:02	*05:01	SSO SBT	
793	Rubocki , Ronald										*02:02	*05:01:01G	SSP	
4251	Schiller , Jennifer	*04:05	*08:14				*04:01	*06:01			*02:02	*05:01:01G	SSO SBT	
747	Tiercy , Jean-Marie	*04:05:01	*08:14	4*01:03	*01:03	*03:03	*04:01:01	*06:01:01			*02:02	*05:01	SSP SSO SBT	DQA1*01:10/03:01/03:02
5451	Tilanus , Marcel G.	*04:05:01	*08:14										SSP SBT	
5642	Varnavidou-Nicolaïd	*04:05	*08:14				*04:01	*06:01					SSP	DRB1*04:80
8052	Yanina Marcos , Ci		*08:14										SSO	
3511	Zeevi , Adriana	*04:05	*08:14	4*01:03	*01:03	*03:01	*04:01	*06:01			*02:02	*05:01	SSP SSO	

Table 8: Individual laboratory results for B-cell #522-Class I

Center	Investigator	Low Resolution						Intermediate/High resolution						METHOD	Other Alleles
		HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C			
5488	Adams , Sharon					*07	*08	*02:03:01	*11:01:01	*15:02:01	*38:02:01			SSP SSO SBT	A*02:427, A*11:12
4691	Al Ajlan , Abdulaziz	*02	*11	*15	*38	*07	*08								
5462	Arnold , Paula							*02:03	*11:01	*15:02	*38:02	*07:02P	*08:01P	SSP SSO SBT	
5133	Askar , Medhat	*02	*11	*15	*38	*07	*08	*02:03:01	*11:01:01	*15:02:01	*38:02:01	*07:02	*08:01	SSO SBT	C*07:02:35, C*08:01:06
774	Cecka , J. Michael	*02	*11	*15	*38	*07	*08	*02:03		*15:02	*38:02				A*02:281/02:315/02:345/0 2:370/02:427/02:431/02:4 63/02:466/02:480/02:505, B*15:214/15:302N, B*38:18
9916	Charlton , Ronald K							*02:03:01	*11:01:01	*15:02:01	*38:02:01	*07:02	*08:01	SSP SBT	
4492	Charron , Dominiqu							*02:03	*11:01	*15:02	*38:02	*07:02	*08:01	SSP SSO	A*02:253/02:264/02:370/0 2:480/02:505, A*11:100/11:120/11:154/1 1:163/11:173, C*07:159/07:195/07:245/0 7:305/07:306, C*08:78/08:79/08:85/08:8 9N/08:95
8021	Clark , Brendan							*02:03	*11:01	*15:02	*38:02	*07:02	*08:01	SSP SSO	
5130	Costeas , Paul A.	*02	*11	*15	*38	*07	*08	*02:03	*11:01	*15:02	*38:02	*07:02	*08:01	SSP SSO	C*08:36N/08:78
779	Daniel , Claude	*02	*11	*15	*38	*07	*08			*15:02				SSP SSO	
5219	Daniel , Dolly	*02	*11	*15	*38	*07	*08								
1108	DeConinck , Martha	*02	*11	*15	*38	*07	*08							SSO	
3766	Dunckley , Heather	*02	*11	*15	*38	*07	*08							SSP SSO RT-PCR	
5214	Eckels/CPMC ,	*02	*11	*15(B75)	*38	*07	*08							SSO	
3135	Enczmann , J							*02:03	*11:01	*15:02	*38:02	*07:02	*08:01	SSP SSO SBT	
792	Gandhi , Manish	*02	*11	*15	*38	*07	*08	*02:03	*11:01	*15:02	*38:02	*07:02	*08:01	SSP SSO SBT	
810	Hamdi , Nuha							*02:03	*11:54	*15:02	*38:02	*07:90	*08:01	SSO	
1694	Hesse , Nicole	*02	*11	*15	*38	*07	*08							SSP	
8043	Hod , Reut	NT												SSP SSO	
2344	Hurley , Hartzman&							*02:03:01	*11:01:01	*15:02:01	*38:02:01	*07:02:01:01	*08:01:01	OTHER	
794	Jaatinen , Taina	*02	*11	*15	*38	*07	*08	*02:03	*11:01	*15:02	*38:02	*07:260	*08:72	SSP SSO SBT RT-PCR	
8086	Jie , Pan							*34:01	*11:01	*15:21	*07:06	*07:02	*04:03	SSP SSO SBT	
2847	Kihara , Masaaki	*02	*11	*15	*38	*07	*08							SSO	
4337	Kim , Tai-Gyu							*02:03	*11:01	*15:02	*38:02	*07:02	*08:01	SBT	
87	Land , Geoffrey A.	*02(A203)	*11	*15(B75)	*38	*07	*08							SSP	
278	Lee , Jar-How	*02	*11	*15	*38	*07	*08	*02:03	*11:01	*15:02	*38:02	*07:02	*08:01		
206	McAlack-Hanau ,	*02	*11	*15	*38	*07	*08								
8042	Muncher , Liora	*02	*11	*15	*38	*07	*08	*02:03	*11:01	*15:02	*38:02	*07:02	*08:01	SSP SSO	
54	Pancoska , Carol	*02	*11	*15	*38	*07	*08	*02:03						SSO	
2400	Phelan , Donna L.	*02	*11	*15	*38	*07	*08	*02:03	*11:01	*15:02	*38:02	*07:02:01G	*08:01:01G		

Table 8: Individual laboratory results for B-cell #522-Class I															
Center	Investigator	Low Resolution						Intermediate/High resolution						METHOD	Other Alleles
		HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C			
3753	Reed , Elaine F.							*02:03	*11:01	*15:02	*38:02	*07:02	NEW	SSO SBT OTHER	A*02:267/02:355/02:427/02:447, A*11:04/11:12/11:20/11:199
3519	Renac , Virginie	*02	*11	*15	*38	*07	*08	*02:03	*11:01	*15:02	*38:02	NEW	NEW	SSP SBT	C*07:02, C*08:01
4251	Schiller , Jennifer	*02	*11	*15	*38	*07	*08	*02:03	*11:01	*15:02	*38:02	*07:02:01G	*08:01:01G	SSO SBT	
8068	Shanmugam , Hem	*02	*11	*15	*38	*07	*08							SSO	
8029	Tarigopula , Anil	*02	*11	*15	*38	*07	*08							SSO	
8052	Yanina Marcos , Ci	*02	*11	*15	*38	*07	*08							SSO	

Cell Exchange #390

The results for Cell Exchange #390 are summarized in Table 9 and Table 10. Molecular typing results for individual laboratories are listed in Ta-

bles 11 -14 for each sample and individual serology results for each sample are listed in Table 15.

Cell 1557. The consensus type for this sample from a Hispanic donor is A*02:01(A1)-A*68:02(A68)-B*15:16(B63)-B*49:01(B49)-C*07:01(Cw7)-C*14:02. One likely association present in this cell is A*68:02-B*49:01-C*07:01, with HF=0.00076, in Hispanics. The other likely association, A*02:01-B*15:16-C*14:02, was observed in previous exchange cells 1153 and 1202.

A2 (100%) and A68 (71%) were the reported A-locus types, with DNA assigning A*02:01 (100%) and A*68:02 (100%). B63 and B49 were well detected by 92% and confirmed as B*15:16 (100%) and B*49:01 (100%). B*15:16:01 was reported by 6 labs. C*07:01 (93%) and C*14:02 (100%) were the C-locus types, with 2 labs reporting C*07:01:01 and 5 labs reporting C*14:02:01.

Cell 1558. The consensus type for this sample from a Hispanic donor is A*32:01(A32)-A*68:01(A68)-B*07:02(B7)-B*35:43(B35)-C*01:02(Cw1)-C*07:02(Cw7). This cell is the half sibling of cell 1491 and cell 1426. From family data, the class I associations in this cell are determined to be A*32:01-B*07:02-C*07:02 and A*68:01-B*35:43-C*01:02. The rare A*68:01-B*35:43-C*01:02 association in this cell is observed exclusively in Hispanics, with HF=0.00020.

This cell was previously typed as cell 1492 (2013), as correctly identified by Claas and Rees. In this present retyping, the assignment of A68 remained relatively the same, as 75% of labs assigned A68, compared to 77% of labs assigning A68 in 2013. A32 (100%) was reported as the second A-locus type, while B7 (100%) and B35 (96%) were reported as the B-locus types. A*32:01, A*68:01, B*07:02, B*35:43, C*01:02, and C*07:02 were all reported in complete consensus by labs reporting at high resolution. A*32:01:01 and B*35:43:01 were each reported by 6 labs.

Cell 1559. The consensus type for this sample from a Hispanic donor is A*02:01(A2)-A*68:01(A68)-B*15:15(B15)-B*39:08(B39)-C*01:02(Cw1)-C*07:17(Cw7). The likely associations present in this cell are A*02:01-B*39:08-C*07:17 and A*68:01-B*15:15-C*01:02, with respective frequencies of 0.00051 and 0.00045, in Hispanics. The A*02:01-B*39:08-C*07:17 association in this cell was observed in cell 1380 (same as cell 1337), also from a Hispanic donor.

B*15:15 was well assigned by 95% of labs reporting at high resolution. However, the serological assignment of this allele remained unresolved as B62 was reported by 42%, B15 by 29%, and B75 by 25%. B39 (83%) was reported as the second B-locus type and confirmed as B*39:08 (100%). A*02:01 (100%) and A*68:01 (100%) were the A-locus types. A*02:01:01 was assigned by 4 labs. A2 (100%) and A68 (67%) were reported by serology. The C-locus types were C*01:02 (100%) and C*07:17 (98%). C*07:17:01 was reported by 6 labs.

Cell 1560. The consensus type for this sample from a Hispanic donor is A*30:02(A30)-A*68:03(A68)-B*08:01(B8)-B*39:05(B39)-C*07:01(Cw7)-C*07:02. Likely associations in this cell are A*30:02-B*08:01-C*07:01 and A*68:03-B*39:05-C*07:02, with respective frequencies of 0.00026 and 0.00653, in Hispanics.

This cell was previously typed as cell 1363 (2009), as noted by Claas and Rees. In this present retyping, the assignment of B39 improved, increasing from 89% in 2009 to 96%. B*39:05 was reported in complete consensus, with 6 labs reporting B*39:05:01. B8 (100%) was reported as the second B-locus type and confirmed as B*08:01 (100%). The assignment of A68 as the A28 split also improved, increasing from 65% in 2009 to 71% in this present typing. A*68:03 (100%) was reported by DNA, with 6 labs reporting A*68:03:01. A30 was reported by 100% and confirmed as A*30:02 (100%). A*30:02:01 was reported by 6 labs. Two subtypes of C*07 were present in this cell, C*07:01 (100%) and C*07:02 (100%).

Table 9. Summary of the 390th Cell Exchange (Cell #1557-1580)

DNA typing

Cell 1557	
27 low/16 high labs - A	%(n)
A*02:01:01	19(3)
A*02:01	81(13)
A*02	100(27)
27 low/16 high labs - A	%(n)
A*68:02:01	19(3)
A*68:02	81(13)
A*68	100(27)
27 low/20 high labs - B	%(n)
B*15:16:01	30(6)
B*15:16	70(14)
B*15(B63)	15(4)
B*15	85(23)
27 low/16 high labs - B	%(n)
B*49:01:01	6 (1)
B*49:01	94(15)
B*49	100(27)
27 low/15 high Labs - C	%(n)
C*07:01:01	13(2)
C*07:01:01G	13(2)
C*07:01P	7 (1)
C*07:01	60(9)
C*07:02	7 (1)
C*07	100(27)
26 low/15 high Labs - C	%(n)
C*14:02:01	33(5)
C*14:02	67(10)
C*14	100(26)

Cell 1558	
27 low/16 high labs - A	%(n)
A*32:01:01	38(6)
A*32:01	62(10)
A*32	100(27)
24 low/16 high labs - A	%(n)
A*68:01:02	6 (1)
A*68:01:02G	19(3)
A*68:01	75(12)
A*68	100(27)
27 low/16 high labs - B	%(n)
B*07:02:01	12(2)
B*07:02:01G	12(2)
B*07:02	75(12)
B*07	100(27)
27 low/19 high labs - B	%(n)
B*35:43:01	32(6)
B*35:43	68(13)
B*35	100(27)
26 low/15 high Labs - C	%(n)
C*01:02:01G	7 (1)
C*01:02P	7 (1)
C*01:02	86(13)
C*01	100(26)
26 low/16 high Labs - C	%(n)
C*07:02:01	19(3)
C*07:02:01G	6 (1)
C*07:02P	6 (1)
C*07:02	69(11)
C*07	100(26)

Cell 1559	
26 low/17 high labs - A	%(n)
A*02:01:01	24(4)
A*02:01 :01G	6 (1)
A*02:01	70(12)
A*02	100(26)
26 low/17 high labs - A	%(n)
A*68:01:02	6 (1)
A*68:01:02G	12(2)
A*68:01	82(14)
A*68	100(26)
24 low/22 high labs - B	%(n)
B*15:15	95(22)
B*15:08+	5(1)
B*15(B62)	13(3)
B*15	87(21)
24 low/20 high labs - B	%(n)
B*39:08	100(20)
B*39	100(24)
24 low/17 high Labs - C	%(n)
C*01:02:01G	6 (1)
C*01:02P	6 (1)
C*01:02	88(17)
C*01	100(24)
24 low/18 high Labs - C	%(n)
C*07:17:01	33(6)
C*07:17	56(10)
C*07:02	11(2)
C*07	100(24)

Cell 1560	
25 low/17 high labs - A	%(n)
A*30:02:01	35(6)
A*30:02	65(11)
A*30	100(25)
25 low/17 high labs - A	%(n)
A*68:03:01	35(6)
A*68:03	65(11)
A*68	100(25)
25 low/17 high labs - B	%(n)
B*08:01:01	6 (1)
B*08:01	94(16)
B*08	100(25)
24 low/18 high labs - B	%(n)
B*39:05:01	33(6)
B*39:05	67(12)
B*39	100(24)
26 low/16 high Labs - C	%(n)
C*07:01:01	19(3)
C*07:01:01G	6 (1)
C*07:01P	6 (1)
C*07:01	69(11)
C*07	100(26)
17 high Labs - C	%(n)
C*07:02:01G	12(2)
C*07:02:01	23(4)
C*07:02P	6 (1)
C*07:02	59(10)

Table 10. Summary of the 390th Cell Exchange (Cell #1557-1560)

Serological typing

(Hispanic) Cell 1557 (24 Samples Typed)	
A2	100.0%
	[100.0%]
A68	70.8%
A28	29.2%
	[100.0%]
B63	91.7%
B15	4.2%
	[95.8%]
B49	91.7%
B21	8.3%
	[100.0%]
Cw7	50.0%
Bw4	79.2%
Others Found	
Cw5	4.2%
Bw6	4.2%
B45	4.2%

(Hispanic) Cell 1558 (24 Samples Typed)	
A32	100.0%
	[100.0%]
A68	75.0%
A28	25.0%
	[100.0%]
B7	100.0%
	[100.0%]
B35	95.8%
Cw1	50.0%
Cw7	50.0%
Bw6	79.2%
Others Found	
Bw4	16.7%
B70	4.2%

(Hispanic) Cell 1559 (24 Samples Typed)	
A2	100.0%
	[100.0%]
A68	66.7%
A28	33.3%
	[100.0%]
B15	29.2%
B62	41.7%
B75	25.0%
	[95.8%]
B39	83.3%
B16	4.2%
	[87.5%]
Cw1	54.2%
Cw7	45.8%
Bw6	79.2%
Others Found	
B35	4.2%

(Hispanic) Cell 1560 (24 Samples Typed)	
A30	100.0%
	[100.0%]
A68	70.8%
A28	29.2%
	[100.0%]
B8	100.0%
B39	91.6%
B39V	4.2%
B16	4.2%
	[100.0%]
Cw7	50.0%
Bw6	79.2%
Others Found	
Cw17	4.2%
B35	4.2%

Table 11. Individual laboratory results for Cell #1557

Center	Investigator	Low Resolution						High Resolution						Method	Other Alleles
		HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C			
5462	Arnold , Paula							*02:01	*68:02	*15:16	*49:01	*07:01	*14:02	SSP SSO SBT OTHER	
5133	Askar , Medhat	*02	*68	*15	*49	*07	*14	*02:01	*68:02	*15:16:01	*49:01	*07:01	*14:02:01	SSO SBT	
8038	Cao , Kai	*02	*68	*15	*49	*07	*14	*02:01:01	*68:02:01	*15:16:01	*49:01	*07:01P	*14:02:01	SSO SBT	
774	Cecka , J. Michael	*02	*68	*15	*49	*07	*14			*15:16				SSP SSO	
8070	Chang , Uckjin							*02:01	*68:02	*15:16	*49:01	*07:01	*14:02	SBT	
4492	Charron , Dominique	*02	*68	*15	*49	*07	*14			*15:16				SSP	B*15:67/15:95/15:222/15:232 /15:254
798	Claas , F.H.J.							*02:01:01	*68:02:01	*15:16:01	*49:01:01	*07:01:01	*14:02:01	SBT	
3632	Colombe , Beth W.	*02	*68	*15	*49	*07	*14	*02:01	*68:02	*15:16	*49:01	*07:01	*14:02	SSP SSO	
779	Daniel , Claude	*02	*68	*15	*49	*07	*14			*15:16				SSO	
3766	Dunckley , Heather	*02	*68	*15	*49	*07	*14							SSO	
5214	Eckels/CPMC	*02	*68	*15(B63)	*49	*07	*14							SSO	
762	Fischer , Gottfried	*02	*68	*15	*49	*07	*14							SSP SSO SBT	
4079	Fort , Marylise	*02	*68	*15	*49	*07	*14							SSP SSO	A*02:93/02:95/02:211:01, B*49:28/49:29/49:30, C*07:257
3545	Goldstein , Steven	*02	*68	*15	*49	*07	*14	*02:01	*68:02	*15:16	*49:01	*07:01	*14:02	SSO SBT	C*07:06/*07:18/*07:343
810	Hamdi , Nuha							*02:01	*68:02	*15:16	*49:01	*07:02	*14:02	SSO	A*02:01L/02:09/*02:43N/*02: 125N, B*49:04/49:30
8043	Hod , Reut	*02	*68	*15	*49	*07	*14							SSP SSO	
771	Israel , Shoshana	*02	*68	*15	*49	*07	*14	*02:01	*68:02	*15:16	*49:01	*07:01:01G	*14:02	SSO SBT	
725	Lardy , N.M.	*02	*68	*15	*49	*07	*14							SSP SSO	
745	Latham , Katy					*07		*02:01:01	*68:02:01	*15:16:01	*49:01		*14:02:01	SSP SBT	
278	Lee , Jar-How	*02	*68	*15	*49	*07	*14	*02:01	*68:02	*15:16	*49:01	*07:01	*14:02		
6649	Lim , Young Ae	*02	*68	*15	*49									SSP	
731	Loewenthal , Ron							*02:01	*68:02	*15:16:01	*49:01	*07:01	*14:02:01		
759	Lopez-Cepero , May	*02	*68	*15(B63)	*49	*07	*14							SSP	
54	Pancoska , Carol	*02	*68	*15(B63)	*49	*07	*14								
8001	Rao , Prakash	*02	*68	*15(B63)	*49	*07	*14							SSP SSO	
3625	Rees , Tracey	*02	*68	*15	*49	*07	*14	*02:01	*68:02	*15:16	*49:01	*07:01	*14:02		
1160	Rosen-Bronson , Sa	*02	*68	*15	*49	*07	*14	*02:01	*68:02	*15:16	*49:01			SSO SBT	
793	Rubocki , Ronald	*02	*68	*15	*49	*07	*14							SSP	
4251	Schiller , Jennifer	*02	*68	*15	*49	*07	*14	*02:01	*68:02	*15:16	*49:01	*07:01:01G	*14:02	SSO SBT	
3808	Thornton , Alycia	*02	*68	*15	*49	*07	*14			*15:16		*07:01			
5642	Varnavidou-Nicolaïd	*02	*68	*15	*49	*07	*14							SSP	
3186	Watson , Narelle	*02	*68	*15	*49	*07	*14							SSO	
16	Zhang, Aiwen	*02	*68	*15	*49	*07	*14	*02:01	*68:02	*15:16:01	*49:01	*07:01:01	*14:02		C*07:16/07:73, C*14:13/14:18/14:23

Table 12. Individual laboratory results for Cell #1558

Center	Investigator	Low Resolution						High Resolution						Method	Other Alleles
		HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C			
5462	Arnold , Paula							*32:01	*68:01	*07:02	*35:43	*01:02	*07:02	SSP SSO SBT OTHER	C*07:61/07:161N
5133	Askar , Medhat	*32	*68	*07	*35	*01	*07	*32:01:01	*68:01:02G	*07:02:01	*35:43:01	*01:02	*07:02:01	SSO SBT	C*01:85, C*07:349
8038	Cao , Kai	*32	*68	*07	*35	*01	*07	*32:01:01	*68:01:02G	*07:02:01G	*35:43:01	*01:02P	*07:02P	SSO SBT	
774	Cecka , J. Michael	*32	*68	*07	*35	*01	*07				*35:43			SSP SSO	B*35:67/35:79/35:86/35:102/35:117
8070	Chang , Uckjin							*32:01	*68:01	*07:02	*35:43	*01:02	*07:02	SBT	
4492	Charron , Dominique	*32	*68	*07	*35	*01	*07				*35:43			SSP	B*35:44/35:67/35:79/35:86/35:102/35:117
798	Claas , F.H.J.							*32:01:01	*68:01:02	*07:02:01	*35:43:01	*01:02	*07:02	SBT	
3632	Colombe , Beth W.	*32	*68	*07	*35	*01	*07	*32:01	*68:01	*07:02	*35:43	*01:02	*07:02	SSP SSO	
779	Daniel , Claude	*32	*68	*07	*35	*01	*07							SSO	
3766	Dunckley , Heather	*32	*68	*07	*35	*01	*07							SSO	
5214	Eckels/CPMC	*32	*68	*07	*35	*01	*07							SSO	
762	Fischer , Gottfried	*32	*68	*07	*35	*01	*07							SSP SSO SBT	
4079	Fort , Marylise	*32	*68	*07	*35	*01	*07							SSP SSO	A*32:47/32:60, A*68:19/68:89, C*01:66/01:70/01:81/01:93
3545	Goldstein , Steven	*32	*68	*07	*35	*01	*07	*32:01	*68:01	*07:02	*35:43	*01:02	*07:02	SSO SBT	B*07:61/07:161N, C*01:85, B*07:50/07:349
810	Hamdi , Nuha							*32:01	*68:01	*07:02	*35:43	*01:02	*07:02	SSO	
8043	Hod , Reut	*32	*68	*07	*35	*01	*07							SSP SSO	
771	Israel , Shoshana	*32	*68	*07	*35	*01	*07	*32:01	*68:01	*07:02	*35:43	*01:02	*07:02	SSO SBT	
725	Lardy , N.M.	*32	*68	*07	*35	*01	*07							SSP SSO	
745	Latham , Katy							*32:01:01	*68:01	*07:02	*35:43:01	*01:02	*07:02:01	SSP SBT	
278	Lee , Jar-How	*32	*68	*07	*35	*01	*07	*32:01	*68:01	*07:02	*35:43	*01:02	*07:02		
6649	Lim , Young Ae	*32	*68	*07	*35									SSP	
731	Loewenthal , Ron							*32:01:01	*68:01:02G	*07:02	*35:43:01	*01:02	*07:02:01		A*68:11N
759	Lopez-Cepero , Ma	*32	*68	*07	*35	*01	*07							SSP	
54	Pancoska , Carol	*32	*68	*07	*35	*01	*07								
8001	Rao , Prakash	*32	*68	*07	*35	*01	*07							SSP SSO	
3625	Rees , Tracey	*32	*68	*07	*35	*01	*07	*32:01	*68:01	*07:02	*35:43	*01:02	*07:02		A*68:11N, B*07:61/07:161N
1160	Rosen-Bronson , Sa	*32	*68	*07	*35	*01	*07	*32:01	*68:01	*07:02	*35:43			SSO SBT	B*07:61
793	Rubocki , Ronald	*32	*68	*07	*35	*01	*07							SSP	
4251	Schiller , Jennifer	*32	*68	*07	*35	*01	*07	*32:01	*68:01	*07:02:01G	*35:43	*01:02:01G	*07:02:01G	SSO SBT	
3808	Thornton , Alycia	*32	*68	*07	*35	*01	*07				*35:43		*07:02		
5642	Varnavidou-Nicolaïd	*32	*68	*07	*35	*01	*07							SSP	
3186	Watson , Narelle	*32	*68	*07	*35	*01	*07							SSO	
16	Zhang, Aiwen	*32	*68	*07	*35	*01	*07	*32:01:01	*68:01	*07:02	*35:43:01	*01:02	*07:02		B*07:61/07:161N, C*01:17/01:54/01:58/01:60, C*07:17:01/*07:29/07:39/07:51

Table 13. Individual laboratory results for Cell #1559

Center	Investigator	Low Resolution						Intermediate/High Resolution						Method	Other Alleles
		HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C			
5462	Arnold , Paula							*02:01	*68:01	*15:15	*39:08	*01:02	*07:17	SSP SSO SBT OTHER	
5133	Askar , Medhat	*02	*68	*15	*39	*01	*07	*02:01	*68:01	*15:15	*39:08	*01:02	*07:17:01	SSO SBT	A*02:22:01, A*68:08:02, C*01:85
8038	Cao , Kai	*02	*68	*15	*39	*01	*07	*02:01:01	*68:01:02G	*15:15	*39:08	*01:02P	*07:17:01	SSO SBT	
774	Cecka , J. Michael	*02	*68	*15	*39	*01	*07			*15:15	*39:08			SSP SSO	
8070	Chang , Uckjin							*02:01	*68:01	*15:15	*39:08	*01:02	*07:17	SBT	
4492	Charron , Dominique	*02	*68	*15	*39	*01	*07			*15:08/11/15+				SSP	
798	Claas , F.H.J.							*02:01:01	*68:01	*15:15	*39:08	*01:02	*07:17:01	SBT	
3632	Colombe , Beth W.	*02	*68	*15	*39	*01	*07	*02:01	*68:01	*15:15	*39:08	*01:02	*07:17	SSP SSO	
779	Daniel , Claude	*02	*68	*15	*39	*01	*07			*15:15	*39:08			SSO	
3766	Dunckley , Heather	*02	*68	*15	*39	*01	*07							SSO	
5214	Eckels/CPMC	*02	*68			*01	*07			*15:15	*39:08			SSO	
762	Fischer , Gottfried							*02:01:01	*68:01:02	*15:15	*39:08	*01:02	*07:17	SSP SSO SBT	A*02:01:01:02L, C*01:85
4079	Fort , Marylise	*02	*68											SSP SSO	C*01:93
3545	Goldstein , Steven	*02	*68	*15	*39	*01	*07	*02:01	*68:01	*15:15	*39:08	*01:02	*07:17	SSO SBT	A*02:22, A*68:08, C*01:85
810	Hamdi , Nuha							*02:01	*68:01	*15:15	*39:08	*01:02	*07:02	SSO	
8043	Hod , Reut	*02	*68	*15	*39	*01	*07							SSP SSO	
771	Israel , Shoshana	*02	*68	*15	*39	*01	*07	*02:01	*68:01	*15:15	*39:08	*01:02	*07:17	SSO SBT	
725	Lardy , N.M.	*02	*68	*15	*39	*01	*07							SSP SSO	
745	Latham , Katy							*02:01:01	*68:01	*15:15	*39:08	*01:02	*07:17:01	SSP SBT	
278	Lee , Jar-How	*02	*68	*15	*39	*01	*07	*02:01	*68:01	*15:15	*39:08	*01:02	*07:17		
6649	Lim , Young Ae	*02	*68	*15	*39									SSP	
731	Loewenthal , Ron							*02:01:01G	*68:01:02G	*15:15	*39:08	*01:02	*07:17:01		
759	Lopez-Cepero , May	*02	*68	*15(B62)	*39	*01	*07							SSP	
54	Pancoska , Carol	*02	*68	*15(B62)	*39	*01	*07								
8001	Rao , Prakash	*02	*68	*15(B62)	*39	*01	*07							SSP SSO	
3625	Rees , Tracey	*02	*68	*15	*39	*01	*07	*02:01	*68:01	*15:15	*39:08	*01:02	*07:17		A*68:11N
1160	Rosen-Bronson , Sa	*02	*68	*15	*39	*01	*07	*02:01	*68:01	*15:15	*39:08	*01:02	*07:17	SSO SBT	A*02:22, A*68:08
793	Rubocki , Ronald	*02	*68	*15	*39	*01	*07							SSP	
4251	Schiller , Jennifer	*02	*68	*15	*39	*01	*07	*02:01	*68:01	*15:15	*39:08	*01:02:01G	*07:17	SSO SBT	
3808	Thornton , Alycia	*02	*68	*15	*39	*01	*07			*15:15			*07:02		
5642	Varnavidou-Nicolaic	*02	*68	*15	*39	*01	*07							SSP	
3186	Watson , Narelle	*02	*68	*15	*39	*01	*07							SSO	
16	Zhang, Aiwen	*02	*68	*15	*39	*01	*07	*02:01	*68:01	*15:15	*39:08	*01:02	*07:17:01		A*02:22/02:246/02:334, A*68:08/68:105/68:104:01

Table 14. Individual laboratory results for Cell #1560

Center	Investigator	Low Resolution						High Resolution						Method	Other Alleles
		HLA-A		HLA-B		HLA-C		HLA-A		HLA-B		HLA-C			
5462	Arnold , Paula							*30:02	*68:03	*08:01	*39:05	*07:01	*07:02	SSP SSO SBT OTHER	
5133	Askar , Medhat	*30	*68	*08	*39	*07	*07	*30:02:01	*68:03:01	*08:01	*39:05:01	*07:01:01	*07:02:01	SSO SBT	C*07:349
8038	Cao , Kai	*30	*68	*08	*39	*07	*07	*30:02:01	*68:03:01	*08:01	*39:05:01	*07:01P	*07:02P	SSO SBT	
774	Cecka , J. Michael	*30	*68	*08	*39	*07								SSP SSO	
8070	Chang , Uckjin							*30:02	*68:03	*08:01	*39:05	*07:01	*07:02	SBT	
4492	Charron , Dominique	*30	*68	*08	*39	*07								SSP	
798	Claas , F.H.J.							*30:02:01	*68:03:01	*08:01:01	*39:05:01	*07:01:01	*07:02:01	SBT	
3632	Colombe , Beth W.	*30	*68	*08	*39	*07	*07	*30:02	*68:03	*08:01	*39:05	*07:01	*07:02	SSP SSO	
779	Daniel , Claude	*30	*68	*08	*39	*07	*07							SSO	
3766	Dunckley , Heather	*30	*68	*08	*39	*07	*07							SSO	
5214	Eckels/CPMC	*30	*68	*08		*07	*07				*39:05			SSO	
762	Fischer , Gottfried							*30:02	*68:03	*08:01	*39:05	*07:01	*07:02	SSP SSO SBT	C*07:50/349, C*07:06/07:18/07:343
4079	Fort , Marylise					*07	*07							SSP SSO	A*30:33, B*08:109/08:121/08:127/ 08:131
3545	Goldstein , Steven	*30	*68	*08	*39	*07	*07	*30:02	*68:03	*08:01	*39:05	*07:01	*07:02	SSO SBT	C*07:06/07:18/07:343, C*07:50/07:349
810	Hamdi , Nuha							*30:02	*68:03	*08:01	*39:05	*07:01	*07:02	SSO	
8043	Hod , Reut	*30	*68	*08	*39	*07								SSP SSO	
771	Israel , Shoshana	*30	*68	*08	*39	*07	*07	*30:02	*68:03	*08:01	*39:05	*07:01	*07:02	SSO SBT	
725	Lardy , N.M.	*30	*68	*08	*39	*07								SSP SSO	
745	Latham , Katy					*07		*30:02:01	*68:03:01	*08:01	*39:05:01		*07:02:01	SSP SBT	
278	Lee , Jar-How	*30	*68	*08	*39	*07	*07	*30:02	*68:03	*08:01	*39:05	*07:01	*07:02		
6649	Lim , Young Ae	*30	*68	*08	*39									SSP	
731	Loewenthal , Ron							*30:02:01	*68:03:01	*08:01	*39:05:01	*07:01	*07:02:01G		
759	Lopez-Cepero , May	*30	*68	*08	*39	*07								SSP	A*02
54	Pancoska , Carol	*30	*68	*08	*39	*07									
8001	Rao , Prakash	*30	*68	*08	*39	*07								SSP SSO	
3625	Rees , Tracey	*30	*68	*08	*39	*07	*07	*30:02	*68:03	*08:01	*39:05	*07:01	*07:02		B*08:08N, C*07:347N/07:349
1160	Rosen-Bronson , Sa	*30	*68	*08	*39	*07		*30:02	*68:03	*08:01	*39:05			SSO SBT	
793	Rubocki , Ronald	*30	*68	*08	*39	*07								SSP	
4251	Schiller , Jennifer	*30	*68	*08	*39	*07	*07	*30:02	*68:03	*08:01	*39:05	*07:01:01G	*07:02:01G	SSO SBT	
3808	Thornton , Alycia	*30	*68	*08	*39	*07	*07					*07:01	*07:02		
5642	Varnavidou-Nicolaïd	*30	*68	*08	*39	*07								SSP	
3186	Watson , Narelle	*30	*68	*08	*39	*07	*07							SSO	
16	Zhang, Aiwen	*30	*68	*08	*39	*07	*07	*30:02:01	*68:03:01	*08:01	*39:05:01	*07:01:01	*07:02:01		B*08:23, B*39:01

Table 15. Individual laboratory results for Cell #1557-1560 by serology

Investigator	Days Old	Cell No 1557 (Hispanic)										Cell No 1558 (Hispanic)								Cell No 1559 (Hispanic)								Cell No 1560 (Hispanic)							
		Viab %	A2	A68	B63	B49	Cw7	Cw14	Bw4	OTHERS	Viab %	A32	A68	B7	B35	Cw1	Cw7	Bw6	OTHERS	Viab %	A2	A68	B15	B39	Cw1	Cw7	Bw6	OTHERS	Viab %	A30	A68	B8	B39	Cw7	Bw6
Bengochea, Ca		100	+	+	+	+				100	+	+	+	+					100	+	+	+						100	+	+	+	+			
Cecka, J. Mic	2	95	+	+	+	+		+		95	+	+	+	+			+		95	+	+	B75	+			+	95	+	+	+	+		+		
Charron, Domi		98	+	+	+	+				95	+	+	+	+					92	+	+	+	B16				95	+	A28	+	B16				
Claas, F.H.J.	6	90	+	A28	+	+		+		90	+	+	+	+	+		+		90	+	A28	B62	+	+		+	90	+	+	+	+		+		
Dunckley, Hea		95	+	+	+	+				95	+	+	+	+					95	+	+	B62	+				95	+	+	+	+				
Enczmann, J	8	75	+	+	+	+				80	+	+	+	+					70	+	+	B62	+				75	+	+	+	+				
Fort, Marylis	3	98	+	+	+	+		+		90	+	+	+	+			+		98	+	+	+	+			+	95	+	+	+	+		+		
Hahn, Amy B.	3	99	+	+	+	+	+	+		99	+	+	+	+	+	+	+	B70	99	+	+	B75	+	+	+	+	99	+	+	+	+	+	+	+	
Kvam, Vonnett		97	+	A28	+	+	+	+		97	+	A28	+	+	+	+	+	Bw4	97	+	A28	+	+	+	+	+	97	+	A28	+	+	+	+		
Latham, Katy	3	80	+	+	+	+		+		80	+	+	+	+			+	Bw4	90	+	+	B62	+			+	80	+	+	+	+	+	+		
Loewenthal ,		70	+	+	+	+	+	+		75	+	A28	+	+	+	+	+		70	+	A28	+	+	+	+	+	80	+	A28	+	+	+	+		
McCoy, Heath	2	98	+	+	+	+	+	+		98	+	+	+	+	+	+	+		98	+	+	B75	+	+	+	+	98	+	+	+	+	+	+		
Pancoska, Car	2	98	+	+	+	+		+		98	+	+	+	+			+		97	+	+	B62	+			+	98	+	+	+	+		+		
Permpikul, Ve	8	80	+	+	+	+		+		80	+	+	+	+			+		80	+	+	+	+			+	80	+	+	+	+		+		
Pule, Ziningi		80	+	+	+	+	+			80	+	+	+	B70		+			75	+	+	B35	+	+	+		80	+	+	+	+	+			
Rees, Tracey	3	80	+	+	+	+	+	+		80	+	+	+	+	+	+	+		90	+	+	B75	+	+	+	+	60	+	+	+	+	+	+		
Renac, Virgin	3	100	+	A28	B15	B21		+		100	+	A28	+	+		+			100	+	A28	+	+		+		100	+	A28	+	+		+		
Rosen-Bronson	2	80	+	+	+	+	+	+		80	+	+	+	+	+	+	+		80	+	+	B62	+	+	+	+	80	+	+	+	+	+	+		
Rubocki, Rona		98	+	A28	+	+	+	+		98	+	A28	+	+	+	+	+		98	+	A28	B62	+	+	+	+	98	+	A28	+	+	+	+		
Shai, Isaac	9	82	+	A28	B45	B21	+	Cw5	+	Bw6	88	+	A28	+	+	+	+	Bw4	82	+	A28	B62		+	+	+	B35	90	+	A28	+	+	+	+	B35>
Thornton, Aly		90	+	A28	+	+	+	+		90	+	+	+	+	+	+	+		90	+	A28	B62	+	+	+	+	90	+	+	+	+	+	+		
Varnavidou-Ni	7	98	+	+	+	+		+		98	+	+	+	+		+	Bw4		98	+	+	B75	+			+	98	+	+	+	+		+		
Vidan-Jeras,	6	100	+	+	+	+	+	+		100	+	+	+	+	+	+	+		100	+	+	B62	+	+	+	+	94	+	+	+	+	+	+		
Watson, Narel	NT																																		
Zhang, Aiwen	2	95	+	A28	+	+	+	+		95	+	A28	+	+	+	+	+		95	+	A28	B75		+	+	+	95	+	A28	+	B39V	+	+		

Serum Exchange #548

The results for **Serum Exchange 548 (sera 1185 - 1188)**, are summarized in Tables 16-21 and individual laboratory results by method are listed

in Tables 22-31. Sera positive to 5C, A25, and B13 were examined in this study.

1185		method	#labs	B57	B46	B62	B63	B75	B50	B56	B55	B13	B35	B49	B53	B58	B77	B37	B41	B44	A1	A23	A25	A29	
class I	NIH-Std	4	75		75																				
	NIH-Ext	3	100	33	100	100	100										33								
	AHG	2	50	50	50	50			50	50	50														
	Luminex	23	96	100	96	96	96	96	100	100	100	100	100	100	100	100	96	100	100	100	100	100	100	100	
	Flow	1	no consensus																						
	ELISA	2	100	100	100	100	100	100	100	100	100	100	100	100	100	100		100	100	100	100	100	50	50	50
	C1q	1	no consensus																						
Other	3	67	67		67	67	67	67	67	67		67	67	67	67	67	67	33	33	33	33	33	33	33	
1185		method	#labs	B45	B51	B52	B71	B72	B42	B38	A36	A43	A11	B15	B17	B76	A80	B59	B67	Cw15	Cw18	Cw4	B78		
class I	NIH-Std	4												25	25										
	NIH-Ext	3														67									
	AHG	2												50	50										
	Luminex	23	100	100	100	96			100	100	100	100				96	100	100	100	96	96	96			
	ELISA	2	100	100	100	100	100						50										100		
	Other	3					67	33	33	33	33	33	33	33											

Sample 1185 was reported to be strongly positive to B57. Additional reactivity to a number of 5C specificities, as well as to B13, B55, and B56 was also strongly detected by various methods. Reactivity to 1C and 12C specificities was reported by Luminex and ELISA. Class II reactivity to DR3 (DR17 and DR18) was reported by Luminex and Luminex PRA. In addition, Luminex reported moderate to weak reactivity to DR52, DR13, and DR14. Several labs noted weak reactivity to DRB3*01:01.

1185		method	#labs	DR18	DR17	DR52	DR13	DR14	DR11
class II	NIH-Ext	1	no specificities assigned						
	Luminex	24	95	89	74	37	37	21	
	Flow	1	no specificities assigned						
	C1q	1	NT						
	Other	2	50	50					

1186		method	#labs	A25	B57	B58	B17	A26	A32	A33	A2	A203	A66	A6601	A6602	A11	A1101	A1102	A34	A68	
class I	NIH-Std	4	25	25		25															
	NIH-Ext	3	67	67	33					33											
	AHG	2	100	50	50	50	50	50	50		50			50							
	Luminex	24	96	96	96		92	96	96	96	21	75	33	33	75	29	29	96	96		
	Flow	1	no consensus																		
	ELISA	2	100	100	100		100	50	50	100		50			50			50	50		
	C1q	1	no consensus																		
Other	3	67	67	67		33	67	67	67		67			67			67	67			
1186		method	#labs	A74	A29	A31	A1	A24	A2403	B63	B75	B13	A69	A43	A30	A36	A23	B77	B62	B76	B46
class II	Luminex	23	96	96	96	50	71	21	96	67	29	96	92	83	67	62	58	62	58		50
	ELISA	2	50	50	50	50	50		50	50	50	50									
	Other	3	67	67	67	33	33	33	33	33	33	33	33	33	33	33	33	33			

For **sample 1186**, anti-A25, -B57, and -B58 reactivity was reported by all methods. In addition, reactivity to A2, 10C, and 1C specificities was reported by various methods. Luminex, ELISA and Luminex PRA also reported reactivity to a number of 5C specificities. For class II, reactivity to DQ3 (DQ7, DQ8, and DQ9), DR7, and DR9 was reported by Luminex and Luminex PRA. Strong anti-DR12 and -DR52 reactivity was also reported by Luminex. Several Luminex labs reported allele level reactivity to DRB3*01:01 and DRB3*03:01, and DQA1*02.

1186		method	#labs	DQ7	DQ8	DQ9	DR7	DR9	DR12	DR52	DPw5	DP10	DP9	DPw1	DP13	DP14
class II	NIH-Ext	1	no specificities assigned													
	Luminex	24	100	100	100	100	100	100	100	95	26	21	21	21	16	16
	Flow	1	no specificities assigned													
	C1q	1	NT													
	Other	2	50	50	50	50	50									

1187	method	#abs	B13	B41	B44	B45	B49	A30	A31	B50	B51	B47	B60	B61	B59	B52	B53	Cw18	Cw6	B7	B63	B64	B77	A32
class I	NIH-Std	4	100																	25				
	NIH-Ext	3	33																					
	AHG	2	100	50	50	50	50	50	50	50	50													
	Luminex	24	100	100	100	100	100	100	100	100	88	100	96	96	88	79	29	50	83				25	
	Flow	1	no consensus																					
	ELISA	2	100	100	100	100	50	50	50	50		50	50	50	50									
	C1q	1	no consensus																					
	Other	3	67	67	33	67	67	67	67	67	33	67	67	67	33	33	33	33	33	33	33	33		33

1187	method	#abs	DQ2	DR12	DR7	DR9	DR52	DR18	DR17	DR13	DR14	DQ9	DQ7	DR11	
class II	NIH-Ext	1	no specificities assigned												
	Luminex	24	100	100	100	100	100	79	37	32	21	21	21	11	
	Flow	1	no specificities assigned												
	C1q	1	no consensus												
	Other	2	50	50	50	50									

Sample 1187 was found to be strongly positive to B13. Additional reactivity to B44, B45, B49, A30, A31, and a number of 7C specificities were reported by AHG, Luminex, ELISA and Luminex PRA. Class II reactivity to DQ2, DR7, DR9, and DR12 was reported by Luminex and Luminex PRA. In addition, Luminex reported strong anti-DR52 and -DR18 reactivity. Allele level reactivity to DQA1*02 was also reported by several Luminex labs.

1188	method	#abs	B13	B61	B60	B41	B47	B49	B50	B45	B44	B51	B52	B57	B59	B7	B38	B62	B72	B53	B35	B63	B75
class I	NIH-Std	4	75																				
	NIH-Ext	3	100	67	33																		
	AHG	2	100	50	50	50	50	50	50	50	50												
	Luminex	24	100	96	96	96	100	100	96	100	96	96	96	96	92	96	92	92	92	92	92	88	88
	Flow	1	no consensus																				
	ELISA	2	100	100	50	100	50	100	100	100	100	50	50	50	50		50	50	50	50	50	50	100
	C1q	1	no consensus																				
	Other	3	67	67	67	33	67	67	67	67		33	33	33	33	33							
1188	method	#abs	B37	B58	B78	B18	A43	A26	A66	B71	B77	B39	B56	B81	B73	B46	B12	B27	B48	B40	B21	B55	
	AHG	2															50			50	50		
	Luminex	24	88	71	59	38	42			92	92	83	75	75	54	42							
	ELISA	2	50	50	50			50	50										50	50		50	
	Other	3				33																	

For **sample 1188**, strong reactivity to B13 was reported by all methods. Additional reactivity to B44, B45, 5C and 7C specificities was reported by various methods. Class II reactivity to DR4 was reported by Luminex and Luminex PRA. In addition, strong reactivity to DR53 was reported by Luminex.

1188	method	#abs	DR4	DR53	DP14	DPw5	DR16
class II	NIH-Ext	1	no specificities assigned				
	Luminex	24	100	100	11	11	11
	Flow	1	no specificities assigned				
	C1q	1	NT				
	Other	2	50				

Table 16. Summary of the 548th Serum Exchange (Serum #1185-1188) by NIH-Standard and NIH-Extended - class I

Method: NIH-Standard											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
4 typing Labs			4 typing Labs			4 typing Labs			4 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B57	75%	100%	A25	25%	100%	B13	100%	100%	B13	75%	89%
B62	75%	100%	B17	25%	100%	B7	25%	60%			
B15	25%	100%	B57	25%	60%						
B17	25%	100%									

Method: NIH-Extended											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
3 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B57	100%	100%	B57	67%	100%	B13	33%	100%	B13	100%	100%
B63	100%	100%	A25	67%	75%				B61	67%	100%
B75	100%	100%	B58	33%	100%				B60	33%	60%
B62	100%	80%	A33	33%	50%						
B76	67%	100%									
B46	33%	100%									
B77	33%	100%									

Table 17. Summary of the 548th Serum Exchange (Serum #1185-1188) by Antiglobulin and C1q - class I

Method: Antiglobulin											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
B15	50%	100%	A25	100%	100%	B13	100%	100%	B13	100%	100%
B17	50%	100%	A26	50%	100%	B41	50%	100%	B21	50%	100%
B21	50%	100%	A32	50%	100%	B49	50%	75%	B40	50%	100%
B46	50%	100%	A6601	50%	100%	B45	50%	67%	B41	50%	100%
B62	50%	100%	B17	50%	100%	A30	50%	50%	B47	50%	100%
B63	50%	100%	B57	50%	100%	B44	50%	50%	B49	50%	100%
B70	50%	100%	B58	50%	100%	B51	50%	36%	B50	50%	100%
B50	50%	80%	A2	50%	56%	A31	50%	20%	B60	50%	100%
B57	50%	80%				B50	50%	20%	B61	50%	100%
B55	50%	60%							B45	50%	67%
B56	50%	50%							B12	50%	56%
B7	50%	50%							B44	50%	50%

Method: C1q											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Table 18. Summary of the 548th Serum Exchange (Serum #1185-1188) by Other - class I

*** Serum 1185 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
B13	67%	100%
B35	67%	100%
B46	67%	100%
B49	67%	100%
B50	67%	100%
B53	67%	100%
B56	67%	100%
B57	67%	100%
B58	67%	100%
B63	67%	100%
B72	67%	100%
B75	67%	100%
B77	67%	100%
A1	33%	100%
A11	33%	100%
A23	33%	100%
A24	33%	100%
A25	33%	100%
A29	33%	100%
A30	33%	100%
A32	33%	100%
A33	33%	100%
A34	33%	100%
A36	33%	100%
A43	33%	100%
A66	33%	100%
A68	33%	100%
A69	33%	100%
B18	33%	100%
B27	33%	100%
B37	33%	100%
B38	33%	100%
B39	33%	100%
B41	33%	100%
B42	33%	100%
B44	33%	100%

*** Serum 1186 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
A11	67%	100%
A2	67%	100%
A25	67%	100%
A29	67%	100%
A31	67%	100%
A32	67%	100%
A33	67%	100%
A34	67%	100%
A66	67%	100%
A68	67%	100%
A74	67%	100%
B57	67%	100%
B58	67%	100%
A1	33%	100%
A23	33%	100%
A24	33%	100%
A26	33%	100%
A30	33%	100%
A36	33%	100%
A43	33%	100%
A69	33%	100%
A80	33%	100%
B13	33%	100%
B18	33%	100%
B27	33%	100%
B63	33%	100%
B64	33%	100%
B72	33%	100%
B75	33%	100%
B77	33%	100%
CW15	33%	100%
CW16	33%	100%
CW17	33%	100%
CW4	33%	100%

*** Serum 1187 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
A30	67%	100%
A31	67%	100%
B13	67%	100%
B41	67%	100%
B45	67%	100%
B47	67%	100%
B49	67%	100%
B50	67%	100%
B60	67%	100%
B61	67%	100%
A32	33%	100%
B44	33%	100%
B51	33%	100%
B52	33%	100%
B53	33%	100%
B59	33%	100%
B63	33%	100%
B64	33%	100%
B7	33%	100%
CW18	33%	100%
CW6	33%	100%

*** Serum 1188 ***		
3 typing Labs		
Antigen	Consensus	Inclusion
B13	67%	100%
B45	67%	100%
B47	67%	100%
B49	67%	100%
B50	67%	100%
B60	67%	100%
B61	67%	100%
A1	33%	100%
A11	33%	100%
A30	33%	100%
A31	33%	100%
A32	33%	100%
A33	33%	100%
B18	33%	100%
B41	33%	100%
B51	33%	100%
B52	33%	100%
B57	33%	100%
B59	33%	100%
B64	33%	100%
B7	33%	100%
CW1	33%	100%
CW12	33%	100%
CW16	33%	100%
CW6	33%	100%
CW7	33%	100%

Table 19. Summary of the 548th Serum Exchange (Serum #1185-1188) by Luminex - class I

*** Serum 1185 ***		
23 typing Labs		
Antigen	Consensus	Inclusion
A1	100%	100%
A23	100%	100%
A25	100%	100%
A29	100%	100%
A36	100%	100%
A43	100%	100%
A80	100%	100%
B13	100%	100%
B35	100%	100%
B37	100%	100%
B41	100%	100%
B42	100%	100%
B44	100%	100%
B45	100%	100%
B46	100%	100%
B49	100%	100%
B50	100%	100%
B51	100%	100%
B52	100%	100%
B53	100%	100%
B55	100%	100%
B56	100%	100%
B58	100%	100%
B59	100%	100%
B67	100%	100%
B38	100%	80%
B57	96%	100%
B62	96%	100%
B63	96%	100%
B71	96%	100%
B75	96%	100%
B76	96%	100%
B77	96%	100%
CW15	96%	100%
CW18	96%	100%
CW4	96%	100%

*** Serum 1186 ***		
24 typing Labs		
Antigen	Consensus	Inclusion
A2	96%	100%
A25	96%	100%
A29	96%	100%
A31	96%	100%
A32	96%	100%
A33	96%	100%
A34	96%	100%
A68	96%	100%
A74	96%	100%
B57	96%	100%
B58	96%	100%
B63	96%	100%
A69	96%	75%
A26	92%	100%
A43	92%	100%
A30	83%	50%
A11	75%	100%
A66	75%	100%
A24	71%	50%
A36	67%	100%
B75	67%	100%
A23	62%	100%
B62	62%	100%
B76	58%	100%
B77	58%	100%
A1	50%	100%
A6601	33%	100%
A6602	33%	100%
A1101	29%	100%
A1102	29%	100%
B13	29%	100%
A203	21%	100%
A2403	21%	100%

*** Serum 1187 ***		
24 typing Labs		
Antigen	Consensus	Inclusion
A30	100%	100%
A31	100%	100%
B13	100%	100%
B41	100%	100%
B45	100%	100%
B47	100%	100%
B49	100%	100%
B50	100%	100%
B44	100%	88%
B60	96%	100%
B61	96%	100%
B51	88%	86%
B59	88%	75%
CW6	83%	100%
B52	79%	40%
CW18	50%	100%
B53	29%	100%
B77	25%	100%

*** Serum 1188 ***		
24 typing Labs		
Antigen	Consensus	Inclusion
B13	100%	100%
B45	100%	100%
B47	100%	100%
B49	100%	100%
B41	96%	100%
B44	96%	100%
B50	96%	100%
B51	96%	100%
B60	96%	100%
B61	96%	100%
B27	96%	86%
B7	96%	67%
B57	96%	50%
B62	92%	100%
B76	92%	100%
B77	92%	100%
B72	92%	80%
B52	92%	75%
B53	92%	75%
B71	92%	75%
B35	92%	67%
B59	92%	67%
B38	92%	50%
B63	88%	100%
B75	88%	100%
B37	88%	50%
B39	83%	75%
B48	83%	67%
B56	75%	100%
B81	75%	75%
B58	71%	33%
B73	54%	100%
B78	50%	100%
A43	42%	100%
B46	42%	100%
B18	38%	100%

Table 20. Summary of the 548th Serum Exchange (Serum #1185-1188) by Flow Cytometry and ELISA - class I

Method: Flow Cytometry											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: ELISA											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A1	100%	100%	A25	100%	100%	B13	100%	100%	B13	100%	100%
B13	100%	100%	A26	100%	100%	B41	100%	100%	B41	100%	100%
B35	100%	100%	B57	100%	100%	B44	100%	100%	B44	100%	100%
B37	100%	100%	B58	100%	100%	B45	100%	100%	B45	100%	100%
B41	100%	100%	A2	100%	8%	A30	50%	100%	B50	100%	100%
B44	100%	100%	A1	50%	100%	A31	50%	100%	B61	100%	100%
B45	100%	100%	A11	50%	100%	B47	50%	100%	B75	100%	100%
B46	100%	100%	A29	50%	100%	B49	50%	100%	B49	100%	75%
B49	100%	100%	A31	50%	100%	B50	50%	100%	A26	50%	100%
B50	100%	100%	A32	50%	100%	B59	50%	100%	A66	50%	100%
B52	100%	100%	A33	50%	100%	B60	50%	100%	B27	50%	100%
B53	100%	100%	A34	50%	100%	B61	50%	100%	B35	50%	100%
B55	100%	100%	A66	50%	100%				B37	50%	100%
B56	100%	100%	A68	50%	100%				B38	50%	100%
B57	100%	100%	A69	50%	100%				B47	50%	100%
B58	100%	100%	A74	50%	100%				B48	50%	100%
B62	100%	100%	B46	50%	100%				B51	50%	100%
B63	100%	100%	B62	50%	100%				B52	50%	100%
B71	100%	100%	B63	50%	100%				B53	50%	100%
B72	100%	100%	B75	50%	100%				B55	50%	100%
B75	100%	100%	A24	50%	50%				B57	50%	100%
B78	100%	100%	B13	50%	50%				B58	50%	100%
B51	100%	75%							B59	50%	100%
A11	50%	100%							B60	50%	100%
A23	50%	100%							B62	50%	100%
A25	50%	100%							B63	50%	100%
A26	50%	100%							B72	50%	100%
A29	50%	100%							B78	50%	100%

Table 21. Summary of the 548th Serum Exchange (Serum #1185-1188) by Luminex and Other - class II

Method: Luminex											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
24 typing Labs			24 typing Labs			24 typing Labs			24 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
DR18	95%	100%	DQ9	100%	100%	DQ2	100%	100%	DR4	100%	100%
DR17	89%	100%	DR7	100%	100%	DR12	100%	100%	DR53	100%	41%
DR52	74%	33%	DR9	100%	100%	DR7	100%	100%	DP14	11%	100%
DR13	37%	100%	DR12	100%	88%	DR9	100%	100%	DPW5	11%	100%
DR14	37%	33%	DQ7	100%	76%	DR52	100%	66%	DR16	11%	100%
DR11	21%	100%	DQ8	100%	75%	DR18	79%	100%	DR1	5%	100%
DPW1	11%	100%	DR52	95%	55%	DR17	37%	100%	DQ7	5%	40%
DQ4	11%	100%	DPW5	26%	100%	DR13	32%	100%			
DQ5	11%	100%	DP10	21%	100%	DR14	21%	100%			
DQ6	11%	100%	DP9	21%	100%	DQ9	21%	33%			
DQ7	11%	100%	DPW1	21%	100%	DQ7	21%	20%			
DQ8	11%	100%	DP13	16%	100%	DR11	11%	100%			
DQ9	11%	100%	DP14	16%	100%	DPW6	5%	100%			
DR7	5%	100%	DP17	11%	100%	DR8	5%	100%			
			DPW3	11%	100%						
			DPW6	11%	100%						

Method: Other											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
DR17	50%	100%	DQ7	50%	100%	DQ2	50%	100%	DR4	50%	100%
DR18	50%	100%	DQ8	50%	100%	DR12	50%	100%			
			DQ9	50%	100%	DR7	50%	100%			
			DR7	50%	100%	DR9	50%	100%			
			DR9	50%	100%						

Other = Luminex PRA

Table 22. Summary of the 548th Serum Exchange (Serum #1185-1188) by NIH-Ext, Flow Cytometry, and C1q - class II

Method: NIH-Extended											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no antigens assigned			no antigens assigned			no consensus		

Method: Flow Cytometry											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no antigens assigned			no antigens assigned			no antigens assigned			no antigens assigned		

Method: C1q											
*** Serum 1185 ***			*** Serum 1186 ***			*** Serum 1187 ***			*** Serum 1188 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
NT			NT			no consensus			NT		

Table 23. Individual laboratory results for Serum #1185-#1188 by NIH-Standard and NIH-Extended - class I

Investigator	**** Serum 1185 ****						**** Serum 1186 ****					**** Serum 1187 ****					**** Serum 1188 ****				Method
	% POS	B57	B62	B15	B17	Other	% POS	A25	B17	B57	Other	% POS	B13	B7	Other	% POS	B13	Other			
Claas, F.H.J.	17	+	+				4					21	+	+		8	+		STD		
Thornton, Alycia		+	+						+				+				+		STD		
Vasilescu, Rodica	22			+	+		10			+		5	+			0			STD		
Watson, Narelle	21	+	+				13	+				9	+			7	+		STD		

Investigator	**** Serum 1185 ****						**** Serum 1186 ****					**** Serum 1187 ****					**** Serum 1188 ****				Method
	% POS	B57	B63	B75	B62	B76	Other	% POS	B57	A25	Other	% POS	B13	Other	% POS	B13	B61	Other			
Fort, Marylise	29	+	+	+	+	+	B77,B46	15	+	+		0			3	+			EXT		
Lardy, N.M.	20	+	+	+	+			15		+	A33	13			24	+	+	B60	EXT		
Reed, Elaine F. PhD	26	+	+	+	+	+		14	+		B58	6	+		14	+	+		EXT		

Table 24. Individual laboratory results for Serum #1185-#1188 by Antiglobulin and C1q - class I

	**** Serum 1185 ****															**** Serum 1186 ****														
Investigator	% POS	B15	B17	B21	B46	B62	B63	B70	B50	B57	B55	B56	B7		Other	% POS	A25	B57	B58	A26	A32	A6601	B17	A2					Other	Method
Hahn, Amy B. PhD					+	+			+	+	+	+	+				+	+	+	+	+	+		+						Antiglobulin
Vasilescu, Rodica	27	+	+	+				+								20	+						+							Antiglobulin

	**** Serum 1187 ****															**** Serum 1188 ****														
Investigator	% POS	B13	B41	B49	B45	A30	B44	B51	A31	B50					Other	% POS	B13	B21	B40	B41	B47	B49	B50	B60	B61	B45	B12	B44	Other	Method
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+							+	+	+	+	+	+	+	+	+	+	+	+		Antiglobulin
Vasilescu, Rodica	5	+														5	+													Antiglobulin

	**** Serum 1185 ****															**** Serum 1186 ****																		
Investigator	% POS	B13	B35	B44	B45	B46	B49	B50	B51	B52	B63	B56	B57	B58	B62	B63	B71	B72	B75	B76	B77	B78	Other	% POS	A25	B57	B58					Other	Method	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A1,Cw10,Cw9		+	+	+							C1q

	**** Serum 1187 ****															**** Serum 1188 ****														
Investigator	% POS	B13													Other	% POS	B13	B49											Other	Method
Phelan, Donna L.		+															+	+												C1q

Table 25. Individual laboratory results for Serum #1185-#1188 by Other - class I

	**** Serum 1185 ****														**** Serum 1186 ****																	
Investigator	% POS	B13	B35	B46	B49	B50	B53	B56	B57	B58	B63	B72	B75	B77	Other	% POS	A11	A2	A25	A29	A31	A32	A33	A34	A66	A68	A74	B57	B58	Other	Method	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >		+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,A24,B13,B27 >	Other
Phelan, Donna L.	98															89																Other - LMX PRA
Reed, Elaine F. PhD	98	+	+	+	+	+	+	+	+	+	+	+	+	+	B62	84	+	+	+	+	+	+	+	+	+	+	+	+	+	A26	Other - LMX PRA	

	**** Serum 1187 ****														**** Serum 1188 ****																
Investigator	% POS	A30	A31	B13	B41	B45	B47	B49	B50	B60	B61				Other	% POS	B13	B45	B47	B49	B50	B60	B61							Other	Method
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+				CW6,B44,B51,B52 >		+	+	+	+	+	+	+							CW6,A11,B51,B52 >	Other
Phelan, Donna L.	45															87															Other - LMX PRA
Reed, Elaine F. PhD	50	+	+	+	+	+	+	+	+	+	+					90	+	+	+	+	+	+	+						B41	Other - LMX PRA	

Table 26. Individual laboratory results for Serum #1185 by Luminex - class I

		**** Serum 1185 ****																																						
Investigator	% POS	A1	A23	A25	A29	A36	A43	A80	B13	B35	B37	B41	B42	B44	B45	B46	B49	B50	B51	B52	B53	B55	B56	B58	B59	B67	B38	B57	B62	B63	B71	B75	B76	B77	CW15	CW18	Other	Method		
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX	
Bengochea, Carrette	59	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A24,B78 >	LMX	
Cecka, J. Michael PhD	91	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A24,A66,B78 >	LMX	
Chen, Dong-Feng PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A24,B60 >	LMX	
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Hamdi, Nuha	93	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Libyh/Roulin, Tabary	95	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A24,B61 >	LMX
Loewenthal, Ron M	64	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Martinho, Paiva &	NT																																						LMX	
McCoy, Heather	61	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Pancoska, Carol PhD	77	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Permpikul, Vejbaesy	61	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,B60 >	LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A24,B60 >	LMX
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,CW6,A11,A24 >	LMX

Table 27. Individual laboratory results for Serum #1186 by Luminex - class I

Investigator	% POS	**** Serum 1186 ****																								Other	Method													
		A2	A25	A29	A31	A32	A33	A34	A68	A74	B57	B58	B63	A69	A26	A43	A30	A11	A66	A24	A36	B75	A23	B62	B76			B77	A1	A6601	A6602	A1101	A1102	B13	A203	A2403				
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Bengochea, Carrette	32	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Cecka, J. Michael P	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW16,CW17	LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Hamdi, Nuha	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B46	LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Libyh/Roulin, Tabary	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Loewenthal , Ron M	32	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,B27,A80,B64 >	LMX	
McCoy, Heather	30	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Pancoska, Carol Ph	42	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Permpikul, Vejbaesy	29																																						LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,B46,CW16,CW17 >	LMX
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW4,B46,CW16,CW17 >	LMX

Table 28. Individual laboratory results for Serum #1187 by Luminex - class I

		**** Serum 1187 ****																				
Investigator	% POS	A30	A31	B13	B41	B45	B47	B49	B50	B44	B60	B61	B51	B59	CW6	B52	CW18	B53	B77	Other	Method	
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+			+							LMX
Bengochea, Carretto	17	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+					LMX
Cecka, J. Michael P	44	+	+	+	+	+	+	+	+	+	+	+	+	+		+						LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A80	LMX
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Hamdi, Nuha	44	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+										LMX
Libyh/Roulin, Tabary	44	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Loewenthal , Ron M	16	+	+	+	+	+	+	+	+				+	+							B40	LMX
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		B7,A32,B64,B63	LMX
McCoy, Heather	21	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Pancoska, Carol Ph	25	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Permpikul, Vejbaesy	22	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						LMX
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+										LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+		LMX
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A80	LMX

Table 29. Individual laboratory results for Serum #1188 by Luminex - class I

		**** Serum 1188 ****																																						
Investigator	% POS	B13	B45	B47	B49	B41	B44	B50	B51	B60	B61	B27	B7	B57	B62	B76	B77	B72	B52	B53	B71	B35	B59	B38	B63	B75	B37	B39	B48	B56	B81	B58	B73	B78	A43	B46	Other	Method		
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B8101,B2708	LMX		
Bengochea, Carrette	38	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B703,B8101,B2708,B7801 >	LMX		
Cecka, J. Michael P	56	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	BW4	LMX			
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B54,B55,B67,B18 >	LMX		
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B54,B55,B67 >	LMX		
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B67,BW4,B2708,A6602	LMX		
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B55,B67,B18	LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,BW4	LMX		
Hamdi, Nuha	75	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,A26	LMX			
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B54,B55,B67 >	LMX		
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B2708	LMX		
Libyh/Roulin, Tabary	47	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A26,B8101,BW4,B2708 >	LMX			
Loewenthal , Ron M	33	+	+	+	+	+	+					+								+				+												B40,B15	LMX			
Martinho, Paiva &		+	+	+	+			+	+	+	+		+	+						+				+													CW6,A11,A1,A30 >	LMX		
McCoy, Heather	35	+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+			+	+					+	+			+							LMX		
Pancoska, Carol Ph	53	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Permpikul, Vejbaesy	38	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX		
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A6602	LMX	
Rosen-Bronson, Sai		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B54,B55,B67 >	LMX	
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX	
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,B54,B55,B67 >	LMX	
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A66,B54,B55,B67 >	LMX	
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	CW6,A66,B54,B55 >	LMX

Table 30. Individual laboratory results for Serum #1185 - #1188 by Flow Cytometry and Elisa - class I

Investigator	**** Serum 1185 ****																			**** Serum 1186 ****							Method								
	% POS	A1	B13	B35	B37	B41	B44	B45	B46	B49	B50	B52	B53	B55	B56	B57	B58	B62	B63	B71	B72	B75	B78	B51	Other	% POS		A25	A26	B57	B58	A2	Other		
Eckels/CPMC	96																									96								FC	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+			Elisa	
McCoy, Heather	62	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A24,B60>	45	+	+	+	+	+			A11,A24,A66>	Elisa

Investigator	**** Serum 1187 ****																			**** Serum 1188 ****									Method				
	% POS	B13	B41	B44	B45															Other	% POS	B13	B41	B44	B45	B50	B61	B75		B49	Other		
Eckels/CPMC	63																						96									FC	
Hahn, Amy B. PhD		+	+	+	+																			+	+	+	+	+	+	+	+		Elisa
McCoy, Heather	21	+	+	+	+																	B60,B61,B49>	51	+	+	+	+	+	+	+	+	B60,B48,A66>	Elisa

Table 29. Individual laboratory results for Serum #1185 - #1186 by Luminex - class II

Investigator	**** Serum 1185 ****														**** Serum 1186 ****														Method						
	% POS	DR18	DR17	DR52	DR13	DR14	DR11	DPW1	DQ4	DQ5	DQ6	DQ7	DQ8	DQ9	Other	% POS	DQ9	DR7	DR9	DR12	DQ7	DQ8	DR52	DPW5	DP10	DP9	DPW1	DP13		DP14	DP17	DPW3	DPW6	Other	
Arnold, Paula PhD		+	+	+													+	+	+	+	+	+													LMX
Bengochea, Carrette	28								+	+	+	+	+	+		21	+	+	+	+	+	+													LMX
Cecka, J. Michael P	26	+	+													51	+	+	+	+	+	+													LMX
Chen, Dong-Feng P		+	+	+	+	+											+	+	+	+	+	+		+	+								DQA1*02:01	LMX	
Dunckley, Heather		+	+	+													+	+	+	+	+	+												LMX	
Eckels/CPMC,		+	+	+											DRB3*01		+	+	+	+	+	+												DRB3*01,*03	LMX
Fort, Marylise		+	+	+	+	+	+										+	+	+	+	+	+												LMX	
Hahn, Amy B. PhD		+	+														+	+	+	+	+	+												LMX	
Hamdi, Nuha	34	+	+	+	+	+										49	+	+	+	+	+	+												LMX	
Holdsworth, Rhonda															DRB3*01:01+		+	+	+	+	+	+		+	+	+	+	+	+	+	+	+	+	DP18, DRB3*01:01, *03:01	LMX
Libyh/Roulin, Tabary	26	+	+													69	+	+	+	+	+	+		+	+										LMX
Pancoska, Carol Ph	13	+	+	+												40	+	+	+	+	+	+													LMX
Permpikul, Vejbaesy	3	+	+	+												19	+	+	+	+	+	+													LMX
Phelan, Donna L.		+	+	+													+	+	+	+	+	+												LMX	
Reed, Elaine F. PhD		+	+	+	+	+											+	+	+	+	+	+											DRB3*01:01, *03:01	LMX	
Rosen-Bronson, Sari		+	+	+											DRB3*01:01, DRB3*03:01		+	+	+	+	+	+	+	+			+	+					DRB3*01:01, *03:01	LMX	
Thornton, Alycia		+					+		+	+	+	+	+	+			+	+	+	+	+	+												LMX	
Vather/JHB,		+	+	+	+	+	+								DR7		+	+	+	+	+	+	+	+		+	+	+				+		LMX	
Vather/Pinetown,		+	+	+	+	+											+	+	+	+	+	+	+	+	+	+	+	+	+				DP19	LMX	

Table 30. Individual laboratory results for Serum #1187 - #1188 by Luminex - class II

Investigator	**** Serum 1187 ****												**** Serum 1188 ****						Method			
	% POS	DQ2	DR12	DR7	DR9	DR52	DR18	DR17	DR13	DR14	DQ9	DQ7	Other	% POS	DR4	DR53	DP14	DPW5		DR16	Other	
Arnold, Paula PhD		+	+	+	+	+									+	+						LMX
Bengochea, Carrette	21	+	+	+	+	+			+	+			DR11	10	+	+			+			LMX
Cecka, J. Michael P	57	+	+	+	+	+								17	+	+						LMX
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+			DQA1*02:01		+	+						LMX
Dunckley, Heather		+	+	+	+	+	+	+	+		+	+			+	+						LMX
Eckels/CPMC,		+	+	+	+	+	+								+	+						LMX
Fort, Marylise		+	+	+	+	+	+	+							+	+						LMX
Hahn, Amy B. PhD		+	+	+	+	+	+					+	+		+	+						LMX
Hamdi, Nuha	54	+	+	+	+	+	+					+	+	17	+	+	+			DQ7		LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+					DRB1*13:03, DQA1*02		+	+	+	+				LMX
Libyh/Roulin, Tabary	54	+	+	+	+	+	+							17	+	+						LMX
Pancoska, Carol Ph	27	+	+	+	+	+	+							9	+	+						LMX
Permpikul, Vejbaesy	17	+	+	+	+	+	+							7	+	+						LMX
Phelan, Donna L.		+	+	+	+	+	+								+	+		+				LMX
Reed, Elaine F. PhD		+	+	+	+	+	+						DQA1*02		+	+						LMX
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+		+	+			+	+						LMX
Thornton, Alycia		+	+	+	+	+									+	+			+	DR1		LMX
Vather/JHB,		+	+	+	+	+	+	+	+	+					+	+						LMX
Vather/Pinetown,		+	+	+	+	+	+	+	+	+			DR8,DR11		+	+						LMX

Table 31. Individual laboratory results for Serum #1185 - #1188 by various methods - class II

Investigator	**** Serum 1185 ****				**** Serum 1186 ****							**** Serum 1187 ****						**** Serum 1188 ****			Method
	% POS	DR17	DR18	Other	% POS	DQ7	DQ8	DQ9	DR7	DR9	Other	% POS	DQ2	DR7	DR9	DR12	Other	% POS	DR4	Other	
Eckels/CPMC	67				70							87						19			FC
Phelan, Donna L.	NT				NT								+	+				NT			C1q
Phelan, Donna L.	34				71							74						17			LMX PRA
Reed, Elaine F. PhD	37	+	+		57	+	+	+	+	+		47	+	+	+	+		13	+		LMX PRA
Reed, Elaine F. PhD	52				11							9						13			EXT

Serum Exchange #549

The results for **Serum Exchange 549 (sera 1189 - 1192)**, are summarized in Tables 32-38 and individual laboratory results by method are listed

in Tables 39-50. Sera strongly positive to A2, A19, and A29 were examined in this study.

Sample 1189 was reported to be strongly positive to A2 by all methods. In addition, reactivity to A28 (A68 and A69) and a number of 5C specificities, including B17 (B57 and B58), was detected by various methods. Luminex and ELISA also reported strong reactivity to A32, B13, and 1C specificities. Additional strong reactivity to a number of C-locus specificities (Cw2, Cw4, Cw5, Cw6, Cw15, Cw17, and Cw18) was also reported by Luminex. For

class II, reactivity to DR9 was reported by Luminex, Luminex PRA, and 1 NIH-extended lab. Additional reactivity to a number of DQ specificities (DQ4, DQ5, DQ6, DQ8, DQ9), as well as reactivity to DR1 and DR4, was detected by Luminex and Luminex PRA. In addition, Luminex reported strong anti-DR53 and -DR7 reactivity. Allele level reactivity to DQA1*01 and DQA1*03 was also reported by Luminex.

1189	method	#labs	A2	A68	A69	A28	B57	B58	B17	B62	B35	B53	B72	B50	B63	A24	A25	B45	B46	B49	B71	B75	B52	B51	B13
class I	NIH-Std	4	100			25			25	25							25								
	NIH-Ext	2	100	50	50		50																		
	AHG	3	67	67	33		33	33	33	33				33	33	33									
	Luminex	25	100	100	100		96	96		84	96	96	96	100	96	92	48	84	96	96	96	96	92	88	88
	Flow	1	no specificities assigned																						
	ELISA	2	100	100	100		100	100		100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100
	C1q	1	no consensus																						
	Other	2	50	50	50		50	50		50	50	50	50												

1189	method	#labs	B78	B56	B18	A3	A32	A29	A11	A23	Cw15	Cw17	Cw18	Cw4	Cw6	Cw2	Cw5	B76	B77	B55	A31	A74	B44	B15
	NIH-Ext	2			50																			
	AHG	3		33																				33
	Luminex	25	88	92	44	88	88	80	76	72	100	100	100	100	100	100	96	96	96	92	88	88	84	
	Flow	1	no specificities assigned																					
	ELISA	2	100			100	100	100	100	100														

1189	method	#labs	DQ4	DQ5	DQ6	DQ8	DQ9	DR1	DR4	DR9	DR53	DR7	DR14	DR10	DQ7	DQ2	DR15	DR51
class II	NIH-Ext	1	no consensus															
	Luminex	20	100	90	100	95	95	100	100	100	95	90	60	25	25	20	15	15
	Flow	1	no specificities assigned															
	C1q	1	no consensus															
	Other	2	50	50	50	50	50	50	50	50								

1190	method	#labs	A2	A68	A69	A28	B57	B58	B17	B18	B27	B2708	B37	B63	B65	B49	B50	B51	B35	B44	B45	B52	B13	B62	B64	B72	B53	B78	B59	B47	B46	B38	B54	B55	B56	B71	B39	B67	B75	B76	B77	B82	A24				
class I	NIH-Std	4	100			25			25																																						
	NIH-Ext	2	100	50	50		50																																								
	AHG	3	100	100	33	33	67	67	33	33	33		33	33	33																																
	Luminex	25	100	100	100		100	100		100	96	44	96	84	88	96	96	96	96	96	96	92	92	92	88	88	88	88	84	88	84	84	80	96	96	96	92	88	88	88	88	88	88	68	60		
	Flow	1	no specificities assigned																																												
	ELISA	2	100	100	100		100	100		100	100		100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100	100		
	C1q	1	no consensus																																												
	Other	2	50	50				50																																							

1190	method	#labs	DR11	DR52	DR13	DR14	DR17	DR18	DQ2	DR12	DP14	DP17	DP18	DP28	DPw2	DPw3	DR7	DP10	DP20	DP9	DPw6	DPw4	DP402	
class II	NIH-STD	1	no consensus																					
	NIH-Ext	1	no specificities assigned																					
	Luminex	11	100	100	100	100	95	89	95		100	100	100	100	100	100	100	89	89	89	89	74	45	
	Flow	1	no specificities assigned																					
	C1q	1	no consensus																					
	Other	2	50	50	50	50	50	50	50	50														

For **sample 1190**, strong anti-A2 reactivity was reported by all methods. Additional reactivity to A28 (A68 and A69) and B17 (B57 and B58) was reported by various methods. Luminex and ELISA also detected strong reactivity to B44, B45, as well as to a number of 5C, 7C, and 8C specificities. Anti-DR11 reactivity was reported for this sample by Luminex, Luminex PRA, and 1 NIH-standard lab. In addition, DR13, DR14, DR17, DR18, DR52, and DQ2 reactivity was reported by Luminex and Luminex PRA. Strong reactivity to a number of DP antigens was also reported by Luminex.

Sample 1191 was found to be strongly positive to A31 and A30. Additional reactivity to A29 and number of 10C specificities was reported by various methods. Strong class II reactivity was detected for this sample, as Luminex and Luminex PRA reported strong anti-DQ7, -DR7, -DR8. -DR9, -DR11, -DR12, -DR13, -DR14, -DR17, -DR18, -DR52 reactivity. Weak DQ2 and DQ4 reactivity was also reported. Additional reactivity to a number of DP antigens, as well as to DQA1*04, DQA1*05, DQA1*06, and DPA1*01, was also detected by Luminex.

1191	method	#labs	A31	A30	A29	A33	A25	A26	A66	A6601	A6602	A34	A74	A32	A24	A2403	A80	B8	A43	A23	B45	B57	B58	B37	A68	A1	A2	A34		
class I	NIH-Std	4	100	50	50		50	50							50										50		50			
	NIH-Ext	2	100	100																										
	AHG	3	100	100		67							33																	
	Luminex	25	100	100	100	100	96	96	80	32	32	100	96	96	20	8	8	28	96	88	20	20	20	12						
	Flow	1	no specificities assigned																											
	ELISA	2	100	100	100	50	50	50	50				100	50			50	100								50		50		
	C1q	1	no consensus																											
	Other	2	50	50	50	50	50	50	50			50			50															

1191	method	#labs	DR7	DR8	DR9	DR11	DR12	DR13	DR14	DR17	DR18	DR52	DQ7	DQ2	DQ4	DP17	DP18	DP28	DPw2	DPw4	DP15	DP19	DP20	DP23	DPw3	DP11	DPw1	DP13	DPw6	DQ6	DP401	DP402
class II	NIH-Ext	1	no specificities assigned																													
	Luminex	19	100	100	100	100	100	100	100	95	95	100	100	37	26	100	100	95	89	89	84	74	74	74	58	47	42	42	42	42	21	21
	Flow	1	no specificities assigned																													
	C1q	1	no consensus																													
	Other	2	50	50	50	50	50	50	50	50	50	50	50	50	50																	

For **sample 1192**, strong reactivity to A29 was detected by all methods. In addition, reactivity to 1C and 10C specificities, as well as reactivity to some 7C specificities, was reported by various methods. For class II, Luminex and Luminex PRA reported reactivity to DR7, DR9, DQ4, DQ7, DQ8, and DQ9.

Additional reactivity to a number of DP antigens, as well as allele level reactivity to DQA1*02:01, DPA1*02:01, and DPA1*02:02, was reported by Luminex.

1192	method	#labs	A29	A30	A31	A26	A33	A1	A80	A74	A66	A6601	A34	A10	B42	A36	A3	A11	B7	B55	B81	B35
class I	NIH-Std	3	67																			
	NIH-Ext	2	100	50																		
	AHG	3	100	67	33	67	33	33	33	67	33	33		33								
	Luminex	25	96	100	100	96	100	96	96	92	80	28	100		72	96	96	72	88	72	64	50
	Flow	1	no specificities assigned																			
	ELISA	2	100	50	50	100	50	50	50	100	50	50	50		50	50	50	50	50	50	50	
	C1q	1	no consensus																			
	Other	2	50			50									50							50
1192	method	#labs	B54	A43	A1101	A1102	B67	B56	B82	A6602	B27	B48	B8101	B2708	B60	B8201	A25	B41	B51	B52	B53	
	AHG	3															33					
	Luminex	25	20	100	24	24	72	56	48	32	20	20	12	8	8	8						
	Other	2	50															50	50	50	50	

1192	method	#labs	DR7	DR9	DQ7	DQ8	DQ9	DQ4	DPw1	DPw5	DP19	DP14	DP13	DP9	DP11	DP17	DQ2	DP10	DPw3	DPw6	DR18	DP18	DP401	DPw4	DP15	DP20
class II	NIH-Ext	1	no consensus																							
	Luminex	8	100	100	95	95	95	90	85	85	80	75	75	70	60	60	60	55	55	45	25	25	20	20	15	15
	Flow	1	no specificities assigned																							
	C1q	1	no consensus																							
	Other	2	50	50	50	50	50	50																		

Table 32. Summary of the 549th Serum Exchange (Serum #1189-1192) by NIH-Standard and NIH-Extended - class I

Method: NIH-Standard											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
4 typing Labs			4 typing Labs			4 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	100%	A2	100%	36%	A31	100%	67%	A29	67%	43%
A25	25%	100%	A28	25%	100%	A30	50%	67%			
A28	25%	100%	B17	25%	100%	A25	25%	100%			
B17	25%	100%	B8	25%	100%	A68	25%	67%			
B62	25%	100%				A24	25%	50%			
						A26	25%	50%			
						A2	25%	43%			
						A29	25%	25%			

Method: NIH-Extended											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	95%	A2	100%	95%	A30	100%	100%	A29	100%	67%
A68	50%	100%	A68	50%	100%	A31	100%	86%	A30	50%	40%
A69	50%	100%	A69	50%	100%						
B18	50%	100%	B57	50%	100%						
B57	50%	100%									

Table 33. Summary of the 549th Serum Exchange (Serum #1189-1192) by Antiglobulin, C1q, and Other - class I

Method: Antiglobulin											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
3 typing Labs			3 typing Labs			3 typing Labs			3 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	67%	100%	A2	100%	100%	A30	100%	100%	A29	100%	100%
A68	67%	89%	A68	100%	89%	A31	100%	100%	A26	67%	90%
A69	33%	100%	B57	67%	100%	A33	67%	100%	A30	67%	64%
B15	33%	100%	B58	67%	100%	A74	33%	100%	A74	67%	42%
B17	33%	100%	A28	33%	100%				A10	33%	100%
B50	33%	100%	A69	33%	100%				A31	33%	100%
B56	33%	100%	B17	33%	100%				A66	33%	100%
B57	33%	100%	B37	33%	100%				A6601	33%	100%
B58	33%	100%	B63	33%	100%				A80	33%	100%
B62	33%	100%	B65	33%	100%				A33	33%	75%
B63	33%	100%	B18	33%	86%				A1	33%	67%
A24	33%	86%	B27	33%	80%				A25	33%	50%

Method: C1q											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: Other											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	50%	100%	A2	50%	100%	A25	50%	100%	A26	50%	100%
A68	50%	100%	A68	50%	100%	A26	50%	100%	A29	50%	100%
A69	50%	100%	B58	50%	100%	A29	50%	100%	B35	50%	100%
B35	50%	100%				A30	50%	100%	B41	50%	100%
B53	50%	100%				A31	50%	100%	B42	50%	100%
B57	50%	100%				A32	50%	100%	B51	50%	100%
B58	50%	100%				A33	50%	100%	B52	50%	100%
B62	50%	100%				A34	50%	100%	B53	50%	100%
B72	50%	100%				A66	50%	100%	B54	50%	100%

Table 34. Summary of the 549th Serum Exchange (Serum #1189-1192) by Luminex - class I

*** Serum 1189 ***		
25 typing Labs		
Antigen	Consensus	Inclusion
A2	100%	100%
A68	100%	100%
A69	100%	100%
B50	100%	100%
CW15	100%	100%
CW17	100%	100%
CW18	100%	100%
CW4	100%	100%
CW6	100%	100%
CW2	100%	88%
B35	96%	100%
B46	96%	100%
B49	96%	100%
B53	96%	100%
B57	96%	100%
B58	96%	100%
B63	96%	100%
B71	96%	100%
B72	96%	100%
B75	96%	100%
B76	96%	100%
B77	96%	100%
CW5	96%	50%
B52	92%	100%
B55	92%	100%
B56	92%	100%
A24	92%	75%
A3	88%	100%
A31	88%	100%
A32	88%	100%
A74	88%	100%
B13	88%	100%
B51	88%	100%
B78	88%	100%
B45	84%	100%

*** Serum 1190 ***		
25 typing Labs		
Antigen	Consensus	Inclusion
A2	100%	100%
A68	100%	100%
A69	100%	100%
B57	100%	100%
B58	100%	100%
B18	100%	67%
B50	96%	100%
B55	96%	100%
B27	96%	86%
B51	96%	86%
B37	96%	75%
B49	96%	75%
B54	96%	75%
B35	96%	67%
B56	96%	60%
B44	96%	50%
B52	92%	100%
B71	92%	75%
B13	92%	71%
B45	92%	67%
B39	88%	100%
B62	88%	100%
B64	88%	100%
B65	88%	100%
B67	88%	100%
B72	88%	100%
B75	88%	100%
B76	88%	100%
B77	88%	100%
B53	88%	67%
B59	88%	33%
B46	84%	100%
B78	84%	100%
B47	84%	50%
B63	84%	50%

*** Serum 1191 ***		
25 typing Labs		
Antigen	Consensus	Inclusion
A29	100%	100%
A30	100%	100%
A31	100%	100%
A33	100%	100%
A34	100%	100%
A26	96%	100%
A32	96%	100%
A43	96%	100%
A74	96%	100%
A25	96%	67%
A23	88%	100%
A66	80%	100%
A6601	32%	100%
A6602	32%	100%
B8	28%	100%
A24	20%	100%
B45	20%	100%
B57	20%	100%
B58	20%	100%
B37	12%	100%
A2403	8%	100%
A80	8%	100%

*** Serum 1192 ***		
25 typing Labs		
Antigen	Consensus	Inclusion
A30	100%	100%
A31	100%	100%
A33	100%	100%
A34	100%	100%
A43	100%	100%
A1	96%	100%
A26	96%	100%
A29	96%	100%
A36	96%	100%
A3	96%	67%
A80	96%	67%
A74	92%	100%
B7	88%	100%
A66	80%	100%
B42	72%	100%
B55	72%	100%
B67	72%	100%
A11	72%	50%
B81	64%	100%
B56	56%	100%
B82	48%	100%
A6602	32%	100%
A6601	28%	100%
A1101	24%	100%
A1102	24%	100%
B27	20%	100%
B48	20%	100%
B54	20%	100%
B8101	12%	100%
B2708	8%	100%
B60	8%	100%
B8201	8%	100%

Table 35. Summary of the 549th Serum Exchange (Serum #1189-1192) by Flow Cytometry and ELISA - class I

Method: Flow Cytometry											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: ELISA											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
A2	100%	100%	A2	100%	100%	A29	100%	100%	A26	100%	100%
A68	100%	100%	A68	100%	100%	A30	100%	100%	A29	100%	100%
A69	100%	100%	A69	100%	100%	A31	100%	100%	A74	100%	100%
B13	100%	100%	B13	100%	100%	A74	100%	100%	A1	50%	100%
B35	100%	100%	B18	100%	100%	B8	100%	100%	A11	50%	100%
B46	100%	100%	B35	100%	100%	A1	50%	100%	A3	50%	100%
B49	100%	100%	B37	100%	100%	A25	50%	100%	A31	50%	100%
B50	100%	100%	B44	100%	100%	A26	50%	100%	A33	50%	100%
B53	100%	100%	B45	100%	100%	A32	50%	100%	A34	50%	100%
B57	100%	100%	B57	100%	100%	A33	50%	100%	A36	50%	100%
B58	100%	100%	B58	100%	100%	A34	50%	100%	A66	50%	100%
B62	100%	100%	B59	100%	100%	A66	50%	100%	A6601	50%	100%
B63	100%	100%	B63	100%	100%	A80	50%	100%	A80	50%	100%
B71	100%	100%	B65	100%	100%				B42	50%	100%
B72	100%	100%	B72	100%	100%				B55	50%	100%
B75	100%	100%	B78	100%	100%				B7	50%	100%
B78	100%	100%	B27	100%	75%				B81	50%	100%
A11	100%	75%	B51	100%	75%				A30	50%	50%
B45	100%	75%	B53	100%	75%						
B51	100%	75%	B62	100%	75%						
B52	100%	75%	B64	100%	75%						
A3	100%	65%	B38	50%	100%						
A23	50%	100%	B46	50%	100%						
A24	50%	100%	B47	50%	100%						
A25	50%	100%	B49	50%	100%						
A29	50%	100%	B50	50%	100%						
A32	50%	100%	B52	50%	100%						

Table 36. Summary of the 549th Serum Exchange (Serum #1189-1192) by NIH and Flow Cytometry - class II

Method: NIH-Standard												
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***			
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs			
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	
NT			no consensus			NT			NT			

Method: NIH-Extended												
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***			
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab			
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	
no consensus			no antigens assigned			no antigens assigned			no consensus			

Method: Flow Cytometry												
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***			
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab			
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	
no antigens assigned			no antigens assigned			no antigens assigned			no antigens assigned			

Table 37. Summary of the 549th Serum Exchange (Serum #1189-1192) by C1q and Other - class II

Method: C1q											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
1 typing Lab			1 typing Lab			1 typing Lab			1 typing Lab		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
no consensus			no consensus			no consensus			no consensus		

Method: Other											
*** Serum 1189 ***			*** Serum 1190 ***			*** Serum 1191 ***			*** Serum 1192 ***		
2 typing Labs			2 typing Labs			2 typing Labs			2 typing Labs		
Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion	Antigen	Consensus	Inclusion
DQ4	50%	100%	DQ2	50%	100%	DQ2	50%	100%	DQ4	50%	100%
DQ5	50%	100%	DR11	50%	100%	DQ4	50%	100%	DQ7	50%	100%
DQ6	50%	100%	DR12	50%	100%	DQ7	50%	100%	DQ8	50%	100%
DQ8	50%	100%	DR13	50%	100%	DR11	50%	100%	DQ9	50%	100%
DQ9	50%	100%	DR14	50%	100%	DR12	50%	100%	DR7	50%	100%
DR1	50%	100%	DR17	50%	100%	DR13	50%	100%	DR9	50%	100%
DR4	50%	100%	DR18	50%	100%	DR14	50%	100%			
DR9	50%	100%	DR52	50%	100%	DR17	50%	100%			
						DR18	50%	100%			
						DR52	50%	100%			
						DR7	50%	100%			
						DR8	50%	100%			
						DR9	50%	100%			

Table 38. Summary of the 549th Serum Exchange (Serum #1189-1192) by Luminex - class II

*** Serum 1189 ***		
20 typing Labs		
Antigen	Consensus	Inclusion
DQ6	100%	100%
DR1	100%	100%
DR4	100%	100%
DR9	100%	86%
DQ4	100%	73%
DQ8	95%	100%
DQ9	95%	100%
DR53	95%	82%
DQ5	90%	78%
DR7	90%	50%
DR14	60%	100%
DR10	25%	100%
DQ7	25%	20%
DQ2	20%	20%
DR15	15%	100%
DR51	15%	100%
DQ3	5%	100%

*** Serum 1190 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DP14	100%	100%
DP17	100%	100%
DP18	100%	100%
DP28	100%	100%
DPW2	100%	100%
DPW3	100%	100%
DR11	100%	100%
DR13	100%	100%
DR14	100%	100%
DR52	100%	100%
DR7	100%	100%
DR17	95%	100%
DQ2	95%	90%
DP10	89%	100%
DP20	89%	100%
DP9	89%	100%
DPW6	89%	100%
DR18	89%	100%
DPW4	74%	87%
DP402	45%	100%
DQ7	5%	100%
DR3	5%	100%

*** Serum 1191 ***		
19 typing Labs		
Antigen	Consensus	Inclusion
DP17	100%	100%
DP18	100%	100%
DQ7	100%	100%
DR11	100%	100%
DR12	100%	100%
DR13	100%	100%
DR14	100%	100%
DR52	100%	100%
DR7	100%	100%
DR8	100%	100%
DR9	100%	100%
DP28	95%	100%
DR17	95%	100%
DR18	95%	100%
DPW2	89%	100%
DPW4	89%	100%
DP15	84%	100%
DP19	74%	100%
DP20	74%	100%
DP23	74%	100%
DPW3	58%	86%
DP11	47%	100%
DPW1	42%	92%
DP13	42%	60%
DPW6	42%	50%
DQ2	37%	40%
DQ6	26%	100%
DQ4	26%	25%
DP401	21%	100%
DP402	21%	100%
DP14	5%	100%
DQ5	5%	100%
DR1404	5%	100%
DR15	5%	100%
DR3	5%	100%

*** Serum 1192 ***		
20 typing Labs		
Antigen	Consensus	Inclusion
DR7	100%	100%
DR9	100%	100%
DQ7	95%	100%
DQ8	95%	100%
DQ9	95%	100%
DQ4	90%	75%
DPW1	85%	100%
DPW5	85%	100%
DP19	80%	100%
DP14	75%	100%
DP13	75%	67%
DP9	70%	100%
DP11	60%	100%
DP17	60%	100%
DQ2	60%	40%
DP10	55%	100%
DPW3	55%	33%
DPW6	45%	50%
DR18	25%	100%
DP18	25%	33%
DP401	20%	100%
DPW4	20%	100%
DP15	15%	100%
DP20	15%	100%
DP28	10%	100%
DR11	10%	100%
DR13	10%	100%
DP23	5%	100%
DQ3	5%	100%
DR12	5%	100%
DR14	5%	100%
DR17	5%	100%
DR4	5%	100%
DR53	5%	100%
DR8	5%	100%

Table 39. Individual laboratory results for Serum #1189-1192 by NIH-Standard and NIH-Extended - class I

	**** Serum 1189 ****						**** Serum 1190 ****						**** Serum 1191 ****				**** Serum 1192 ****				
Investigator	% POS	A2	A28	B17	B62	Other	% POS	A2	A28	B17	B8	Other	% POS	A31	A30	Other	% POS	A29	Other	Method	
Claas, F.H.J.	50	+			+	A25	75	+			+		49	+		A24,A2,A25,A26 >	4			STD	
Thornton, Alycia		+						+						+		A29				STD	
Vasilescu, Rodica	61	+	+	+			33	+	+	+			25	+	+		17	+		STD	
Watson, Narelle	52	+					26	+					15	+	+		4	+		STD	

	**** Serum 1189 ****						**** Serum 1190 ****						**** Serum 1191 ****				**** Serum 1192 ****				
Investigator	% POS	A2	A68	A69	B18	Other	% POS	A2	A68	A69	B57	Other	% POS	A30	A31	Other	% POS	A29	A30	Other	Method
Lardy, N.M.	43	+			+	B57	39	+					20	+	+		7	+	+		EXT
Reed, Elaine F. PhD	46	+	+	+			44	+	+	+	+		32	+	+		9	+			EXT

Table 40. Individual laboratory results for Serum #1189-1192 by Antiglobulin and C1q - class I

Investigator	**** Serum 1189 ****											**** Serum 1190 ****											**** Serum 1191 ****						**** Serum 1192 ****											Method
	% POS	A2	A68	A69	B15	B17	B50	B56	B57	B58	Other	% POS	A2	A68	B57	B58	A28	A69	B17	B37	B63	Other	% POS	A30	A31	A33	A74	Other	% POS	A29	A26	A30	A74	A10	A31	A66	A6601	A80	Other	
Cecka, J. Michael P	97											78	+	+	+	+	+				+	B18	35	+	+	+	+			50	+	+	+	+		+	+	+	A25>	Antiglobulin
Hahn, Amy B. PhD		+	+				+	+	+	+	A24>		+	+	+	+				+		B27>		+	+					+	+	+	+			+		A1>	Antiglobulin	
Vasilescu, Rodica	60	+	+	+	+	+						50	+	+				+	+				22	+	+	+			20	+					+				Antiglobulin	

Investigator	**** Serum 1189 ****											**** Serum 1190 ****											**** Serum 1191 ****						**** Serum 1192 ****											Method
	% POS	A2	A68	A69							Other	% POS	A2									Other	% POS	A29	A30	A31	A33	A74	Other	% POS	A26	A29	A30	A43					Other	
Phelan, Donna L.		+	+	+								+												+	+	+	+	+			+	+	+	+						C1q

Table 41. Individual laboratory results for Serum #1189-1192 by Other - class I

Investigator	**** Serum 1189 ****											**** Serum 1190 ****											Method	
	% POS	A2	A68	A69	B35	B53	B57	B58	B62	B72	B75	Other	% POS	A2	A68	B58								Other
Phelan, Donna L.	100												95											Other
Reed, Elaine F. PhD	94	+	+	+	+	+	+	+	+	+	+		84	+	+	+								Other

Investigator	**** Serum 1191 ****											**** Serum 1192 ****											Method	
	% POS	A25	A26	A29	A30	A31	A32	A33	A34	A66	A74	Other	% POS	A26	A29	B35	B41	B42	B51	B52	B53	B54		B60
Phelan, Donna L.	58												82											Other
Reed, Elaine F. PhD	66	+	+	+	+	+	+	+	+	+	+		84	+	+	+	+	+	+	+	+	+	+	B78,B62,B7,B71 >

Other = Luminex PRA

Table 42. Individual laboratory results for Serum #1189 by Luminex - class I

		**** Serum 1189 ****																																												
Investigator	% POS	A2	A68	A69	B50	CW15	CW17	CW18	CW4	CW6	CW2	B35	B46	B49	B53	B57	B58	B63	B71	B72	B75	B76	B77	CW5	B52	B55	B56	A24	A3	A31	A32	A74	B13	B51	B78	B45	B62	B44	A29	Other	Method					
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A203,A2403 >	LMX			
Bengochea, Carrette	56	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,A34,A23,A43 >	LMX			
Cecka, J. Michael P	85	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B67	LMX			
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B48,B47,B27 >	LMX			
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A203,B60,B61 >	LMX		
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B27,B54,B67 >	LMX		
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A66,B47,B27 >	LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B27,B67,A34 >	LMX		
Hamdi, Nuha	82	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B27,B67,A34 >	LMX		
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B60,B61,B48 >	LMX		
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX		
Libyh/Roulin, Taban	69	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A203,B27,B54,B67 >	LMX		
Loewenthal , Ron M	49	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B15	LMX			
Martinho, Paiva &		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B48,A66,B47 >	LMX		
McCoy, Heather	40	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	LMX			
Pancoska, Carol Ph	70	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B27,B67,A34 >	LMX		
Permpikul, Vejbaesy	51	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,CW12	LMX		
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A66,B27,B54 >	LMX		
Pule, Ziningi	46	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B15,A66,B27 >	LMX		
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A66,B47,B27 >	LMX	
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B48,A66,B47 >	LMX	
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A34,A23,B2708	LMX	
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,A203,B48,B47 >	LMX	
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B60,B61,B48 >	LMX	
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A11,B61,B48,A66 >	LMX

Table 44. Individual laboratory results for Serum #1191 by Luminex - class I

Investigator	**** Serum 1191 ****																	Method							
	% POS	A29	A30	A31	A33	A34	A26	A32	A43	A74	A25	A23	A66	A6601	A6602	B8	A24		B45	B57	B58	B37	Other		
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+										LMX
Bengochea, Carrette	19	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+			A2403	LMX	
Cecka, J. Michael P	56	+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX	
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX	
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+					LMX	
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX	
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+			+		+				+		LMX	
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Hamdi, Nuha	56	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+			+		+						LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+				+		+	+				LMX	
Libyh/Roulin, Tabar	51	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX	
Loewenthal , Ron M	19	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+			A2403	LMX	
Martinho, Paiva &		+	+	+	+	+		+		+	+	+	+				+	+				+	CW4,CW6,B13,B27 >	LMX	
McCoy, Heather	18	+	+	+	+	+	+		+	+		+	+											LMX	
Pancoska, Carol Ph	18	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Permpikul, Vejbaesy	18	+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Pule, Ziningi		+	+	+	+	+	+	+	+	+	+	+	+			+	+		+	+				LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+											LMX	
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+			+						+		LMX	
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+						+	+				LMX	
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+									LMX	
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+			+		+					A3,A80	LMX	
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+											LMX	

Table 45. Individual laboratory results for Serum #1192 by Luminex - class I

**** Serum 1192 ****																																					
Investigator	% POS	A30	A31	A33	A34	A43	A1	A26	A29	A36	A3	A80	A74	B7	A66	B42	B55	B67	A11	B81	B56	B82	A6602	A6601	A1101	A1102	B27	B48	B54	B8101	Other	Method					
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+				+					+	+	+	+							LMX			
Bengochea, Carrette	21	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+						+	+	+	+				+			LMX			
Cecka, J. Michael P	65	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+					+	+	+	+							LMX			
Chen, Dong-Feng P		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+		+	+	+	+				+	B8201		LMX			
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B2708		LMX			
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX		
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX		
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX		
Hamdi, Nuha	65	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX	
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX	
Lardy, N.M.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+																				LMX	
Libyh/Roulin, Tabar	65	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				+		+	+	+	+				+	B8201		LMX			
Loewenthal , Ron M	19	+	+	+	+	+		+	+					+										+											LMX		
Martinho, Paiva &		+	+	+	+	+	+		+	+	+	+		+	+	+	+	+	+	+	+	+	+					+	+	+		B60,A32,A68,B8		LMX			
McCoy, Heather	22	+	+	+	+	+	+	+	+	+	+	+		+	+																					LMX	
Pancoska, Carol Ph	30	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX	
Permpikul, Vejbaesy	25	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX	
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX	
Pule, Ziningi	18	+	+	+	+	+	+		+	+	+	+	+		+					+																LMX	
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX	
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX
Vasilescu, Rodica		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B2708		LMX		
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	B60		LMX		
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					LMX

Table 46. Individual laboratory results for Serum #1189-#1192 by Flow Cytometry and ELISA - class I

**** Serum 1189 ****																										
Investigator	% POS	A2	A68	A69	B13	B35	B46	B49	B50	B53	B57	B58	B62	B63	B71	B72	B75	B78	A11	B45	B51	B52	A3	Other	Method	
Eckels/CPMC	95																									FC
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			Elisa
McCoy, Heather	65	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	A24,B48,B44,B27 >	Elisa	

**** Serum 1190 ****																										
Investigator	% POS	A2	A68	A69	B13	B18	B35	B37	B44	B45	B57	B58	B59	B63	B65	B72	B78	B27	B51	B53	B62	B64		Other	Method	
Eckels/CPMC	92																									FC
Hahn, Amy B. PhD	92	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+				Elisa
McCoy, Heather	56	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		A24,B49,B50,B47 >	Elisa	

**** Serum 1191 ****																											
Investigator	% POS	A29	A30	A31	A74	B8																			Other	Method	
Eckels/CPMC	76																										FC
Hahn, Amy B. PhD	76	+	+	+	+	+																			A1,A80	Elisa	
McCoy, Heather	30	+	+	+	+	+																			A66,A25,A26,A34 >	Elisa	

**** Serum 1192 ****																											
Investigator	% POS	A26	A29	A74																					Other	Method	
Eckels/CPMC	83																										FC
Hahn, Amy B. PhD	83	+	+	+																					A30,A6601	Elisa	
McCoy, Heather	28	+	+	+																					A11,A66,B7,B55 >	Elisa	

Table 48. Individual laboratory results for Serum #1191 by C1q and Luminex - class II

**** Serum 1191 ****																								Method		
Investigator	% POS	DP11	DP18	DP19	DP20	DP23	DP28	DPW1	DPW2	DPW3	DPW4	DPW6	DQ2	DQ7	DR11	DR12	DR13	DR14	DR17	DR18	DR52	DR7	DR8	DR9	Other	Method
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			C1q

**** Serum 1191 ****																								Method					
Investigator	% POS	DP17	DP18	DQ7	DR11	DR12	DR13	DR14	DR52	DR7	DR8	DR9	DP28	DR17	DR18	DPW2	DPW4	DP15	DP19	DP20	DP23	DPW3	DP11	DPW1	DP13	DPW6	DQ2	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+										DQA1*04:01, *05:01, DPA1*01:03/*01:04/*01:05, DPA1*03:01	LMX
Bengochea, Carrett	52	+	+	+	+	+	+	+	+	+	+	+	+			+	+					+					+	DR3,DR1404	LMX
Cecka, J. Michael F	100	+	+	+	+	+	+	+	+	+	+	+		+	+	+	+	+				+	+	+	+	+			LMX
Chen, Dong-Feng F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+	+	+	+	+		DP402,DP401, DQA1*04,*05,*06, DPA1*01,*03	LMX
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4,DQ6,DP402,DP401	LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						DPA1*01:03,*03:01,*04:01, DQA1*05:01,*06:01,*04:01	LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX
Hahn, Amy B. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+								LMX
Hamdi, Nuha	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+					DP14,DP402,DP401, DQA1*04,*05,*06, DPA1*01	LMX
Libyh/Roulin, Tabar	97	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	+						DQ6,DP402,DP401	LMX
Pancoska, Carol Ph	49	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DQ4	LMX
Permpikul, Vejbaes	41	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+	+											LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	DR15,DQ4	LMX
Pule, Ziningi																													LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							DPA1*01,*03, DQA1*04,*05, DQB1*06:03, *06:09	LMX
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+					+		DQ6, DQA1*04,*05,*06, DPA1*01	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+					DPA1*01:03, *03:01, *04:01, DQA1*05:01, *06:01, *04:01	LMX
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		DQ5,DQ6	LMX
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							DQ6	LMX

Table 49. Individual laboratory results for Serum #1192 by C1q and Luminex - class II

**** Serum 1192 ****																					
Investigator	% POS	DQ7	DQ8	DQ9	DR7															Other	Method
Phelan, Donna L.		+	+	+	+																C1q

**** Serum 1192 ****																											
Investigator	% POS	DR7	DR9	DQ7	DQ8	DQ9	DQ4	DPW1	DPW5	DP19	DP14	DP13	DP9	DP11	DP17	DQ2	DP10	DPW3	DPW6	DR18	DP18	DP401	DPW4	DP15	DP20	Other	Method
Arnold, Paula PhD		+	+	+	+	+	+	+	+	+			+													DQA1*02:01, DPA1*02:02, *02:01	LMX
Bengochea, Carrett	46	+	+	+	+	+	+	+	+	+	+	+			+								+			DP28	LMX
Cecka, J. Michael F	68	+	+	+	+	+																					LMX
Chen, Dong-Feng F		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+						+			DPA1*02+	LMX
Dunckley, Heather		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		LMX
Eckels/CPMC,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							DQA1*02:01,*03:01, *04:01,*06:01, DPA1*02:02,*02:01,*04:01	LMX
Fort, Marylise		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+						LMX
Hahn, Amy B. PhD		+	+	+	+	+	+		+																		LMX
Hamdi, Nuha	71	+	+	+	+	+	+	+	+	+	+	+	+			+		+	+								LMX
Holdsworth, Rhonda		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+		+	+	DPA1*02	LMX
Libyh/Roulin, Tabar	69	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+						DR8,DR11,DR13,DR14 >	LMX
Pancoska, Carol Ph	45	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+						LMX
Permpikul, Vejbaes	71	+	+	+	+	+		+													+					DR4,DR11,DR12,DR13 >	LMX
Phelan, Donna L.		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+		+						LMX
Pule, Ziningi	43	+	+				+																			DQ3	LMX
Reed, Elaine F. PhD		+	+	+	+	+	+	+	+	+	+	+	+	+		+											LMX
Rosen-Bronson, Sa		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+							DPA1*02	LMX
Thornton, Alycia		+	+	+	+	+	+	+	+	+	+	+			+											DP28	LMX
Vather/JHB,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+			+	+	+	DP23	LMX
Vather/Pinetown,		+	+	+	+	+	+	+	+	+	+	+	+	+	+	+	+										LMX

Table 50. Individual laboratory results for Serum #1189-#1192 by NIH, Flow Cytometry, and Other - class II

Investigator	**** Serum 1189 ****										**** Serum 1190 ****										**** Serum 1191 ****										**** Serum 1192 ****										Method
	% POS	DR9								Other	% POS	DR11	DR3							Other	% POS								Other	% POS	DR7						Other				
Claas, F.H.J.		NT									75	+	+									NT																STD			
Reed, Elaine F. PhD	63	+									71										92																EXT				
Eckels/CPMC	96										93										99																FC				

Investigator	**** Serum 1189 ****										**** Serum 1190 ****										**** Serum 1191 ****										**** Serum 1192 ****										Method
	% POS	DQ4	DQ5	DQ6	DQ8	DQ9	DR1	DR4	DR9	Other	% POS	DQ2	DR11	DR12	DR13	DR14	DR17	DR18	DR52	Other	% POS	DQ2	DQ4	DQ7	DR11	DR12	DR13	DR14	DR17	Other	% POS	DQ4	DQ7	DQ8	DQ9	DR7	DR9	Other			
Phelan, Donna L.	89										91										100																	Other			
Reed, Elaine F. PhD	77	+	+	+	+	+	+	+	+		63	+	+	+	+	+	+	+			73	+	+	+	+	+	+	+	+	DR7,DR8,DR9,DR18 >	67	+	+	+	+	+	+	Other			

Other = Luminex PRA

NEXT MAILING DATE: March 2, 2016
Arlene Locke, David Gjertson, Qiheng Zhang, and Elaine F. Reed